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ABSTRACT 
 
GENERATION OF XANTHOMONAS DERIVED TALE PROTEINS  
THAT INHIBIT GENE TRANSCRIPTION  
 
Şeyda Şaziye Temiz 
Biological Sciences and Bioengineering, MSc. Thesis, 2013  
Thesis supervisor: Batu Erman 
 
Keywords: Golden Gate cloning, IL-7R alpha, NF-kappa B, 
Transcription activator-like effector, TALEN   
 
In the first part of this study, we aimed to mutate several transcription factor 
binding sites in the IL-7R alpha gene locus by generating transcription activator like 
effector (TALE) nucleases (TALEN) targeting these sites. We designed, constructed 
and expressed 3 pairs of TALENs targeting the NF-kappaB, Notch, and glucocorticoid 
receptor (GR) binding sites in the IL7R gene enhancer. We generated cell lines with 
insertion and deletion (INDEL) mutations induced by these TALENs at these target 
sites and determined the effects of these mutations on IL-7R alpha gene expression. We 
assessed TALEN induced mutations in murine Neuro-2a and RLM11 cell lines by a 
modified restriction fragment length polymorphism (RFLP) assay and by DNA 
sequencing. We demonstrate that mutations induced by TALEN pairs targeting the 
IL7R enhancer NF-kappaB site reduce IL-7R alpha gene expression, while mutations in 
the Notch binding site did not change IL-7R expression. In the second part of this study, 
we aimed to inhibit the transcription activation function of the NF-kB protein by 
competitive binding of target sites with TALE proteins. We generated plasmids 
encoding TALE-dsRed fusion proteins that were designed to bind NF-kB binding sites 
in a reporter cell line. TNF-alpha treatment of this cell line results in NF-kB nuclear 
translocation and a resultant increase in GFP fluorescence. TALE-dsRed fusion proteins 
with increasing numbers of DNA binding repeats competed for NF-kB binding to this 
reporter and resulted in reduced GFP expression upon TNF treatment. Our experiments 
demonstrate that TALENs and TALEs can efficiently inhibit gene transcription. 
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ÖZET 
 
GEN TRANSKRİPSİYONUNU BASKILAYAN XANTHOMONAS KÖKENLİ 
 TALE PROTEİNLERİNİN OLUŞTURULMASI 
 
Şeyda Şaziye Temiz 
Biyoloji Bilimleri ve Biyomühendislik, Master Tezi, 2013 
Tez Danışmanı: Batu Erman 
 
Anahtar Kelimeler: Golden Gate klonlama, IL-7R alfa, NF-kappa B, 
 Transcription activator-like effector, TALEN 
 
 Bu çalışmanın ilk bölümünde IL7R alfa gen bölgesindeki çeşitli transkripsiyon 
faktör bağlanma bölgelerinde oluşturulan transcription activator-like effector (TALE) 
nükleaz (TALEN) plazmidleri ile mütasyonlar oluşturmayı amaçladık. IL-7R geninin 
enhancer bölgesindeki NF-kappaB, Notch ve GR bağlanma bölgelerini hedefleyen 3 çift 
TALEN plazmidini oluşturduk. TALEN plazmidlerini hücrede ifade ederek mütasyonlu 
hücre hatları oluşturduk ve bu mütasyonların IL7R ifadesine etkisini araştırdık. Neuro-
2a ve RLM11 hücre hatlarında oluşturduğumuz mütasyonları modifiye edilmiş RFLP 
yöntemi ile DNA sekanslaması ile belirledik. NF-kB bağlanma bölgesindeki 
mütasyonların IL-7R ifadesinde azalmaya neden olduğunu, Notch bağlanma 
bölgesindeki mütasyonların ise IL-7R ifadesini değiştirmediğini gözlemledik. Bu 
çalışmanın ikinci bölümünde, NF-kB proteinlerinin transkripsiyon aktivasyonundaki 
rolünü NF-kB bağlanma bölgelerine kompetitif olarak bağlanan TALE proteinleri ile 
inhibe etmeyi amaçladık. TNF-alfa uygulanmasına NF-kB translokasyonu sonucunda 
GFP ifadesi ile cevap veren reporter hücre hattındaki NF-kB bağlanma bölgesine 
bağlanacak TALE-dsRed füzyon proteinleri ifade eden plazmidler oluşturduk. TALE-
dsRed füzyon proteinlerinin NF-kB proteininin bağlanmasini kompetitif olarak inhibe 
ederek reporter hücrelerde GFP ifadesini azalttığını gözlemledik. Çalışmalarımız, 
TALE ve TALEN proteinlerini gen transkripyonunu baskılayabileceğimizi 
göstermektedir. 
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1. INTRODUCTION 
 
1.1 Transcription Activator like Effectors 
 Transcriptional activator-like (TAL) effector proteins are produced by Gram-
negative bacterial plant pathogens that belong to the genus Xanthomonas which cause 
various diseases in different plant species. These pathogens secrete TAL effector 
proteins through a Hrp (hypersensitive response and pathogenicity)-type III secretion 
system (T3S) into the cytoplasm of host plant cells using a bacterial translocon 
complex. Once translocated to the eukaryotic plant cell, bacterial TAL effector proteins 
interfere with different plant pathways to contribute to infection. Once inside the plant 
cell cytoplasm, TALE proteins translocate to nucleus with the help of a NLS and target 
various elements in the plant genome. By binding to host plant cell gene promoters, 
TAL effector proteins lead to the  transcriptional activation of the  host genes[1]. 
 
1.1.1 Special Structural Features of TAL Effector Proteins 
 TAL effector proteins are composed of an N-terminal translocation domain, a 
central domain with array of repeat units for DNA binding, and a C-terminal region 
containing a nuclear localization signal (NLS) and an acidic transcriptional activation 
domain (Figure1.1).  
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Figure 1.1 Transcription activator-like effector (TALE) protein structure and DNA 
recognition code. TALE proteins from Xanthomonas species consist of an N-terminal 
translocation domain (TD), a central repeat array for DNA binding, a C-terminal 
domain with two nuclear localization signals (NLS) and a transcriptional activation 
domain (AD). Each DNA binding repeat is composed of 34 identical amino acids with 
the exception of the 12th and 13th residues, RVDs that determine DNA binding 
specificity. The consensus repeat sequence is shown in single letter amino acid code 
above the protein schematic, with the RVD underlined. The DNA binding base 
preferences of four common RVDs (coded by colored boxes) are shown[2].  
The characteristic central DNA binding domain of TALE proteins consists of 
tandem repeat units with 34 amino acids residues followed by a single half repeat of 20 
amino acids. In each repeat unit, only two adjacent amino acid residues at position 12 
and 13 are polymorphic and named ‘repeat-variable di-residues’ (RVDs) (Figure 1.2). 
The DNA binding specificity of a TAL effector protein is determined by the number 
and order of the different RVD containing repeats. Each RVD in a repeat recognizes a 
single nucleotide mediated by a code (summarized in Fig.1) that results in specific DNA 
binding. The correlation between the number of repeat units of TALE binding domains 
and the length of its target DNA sequence indicated the presence of a code determining 
RVDs specificity[3]. In 2010, binding specificities of RVDs were validated using 
computational analysis[4]. In naturally occurring TALE proteins, certain RVDs bind to 
their corresponding repeat with high specificity such that HD binds to C, NG binds to T 
and NI binds to A. On the other hand, some RVDs show degeneracy of recognizing two 
different bases or being nonselective towards bases. Repeat units containing NN RVDs 
recognize both A and G bases; whereas NS repeats recognizes all four base pairs.  
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Figure 1.2 Tandem repeats in the DNA binding domain of TALE protein from 
Xanthomonas axonopodispv. citri str. 306 (gb|AAM39243.1). Each repeat consists of 34 
amino acid residues, where the 12th and 13thare polymorphic, repeat variable di-residues 
(RVDs) (highlighted according to the code given in Fig 1.1 for amino acid recognition). 
Amino acid sequence at the bottom is the consensus. 
Comparison of naturally occurring TALE protein RVD sequences and the 
corresponding DNA binding sites at the promoters of host genes indicates that at a gross 
level, the code of ‘one RVD to one base’ is not context dependent; in other words, base 
preference of one RVD is not affected by the preference of adjacent RVDs. However, a 
big unknown in TALE protein DNA binding is whether all RVDs must contact their 
corresponding bases or whether ‘mismatches’ can be allowed for efficient binding. 
Most recognition sites of naturally occurring TALEs are preceded by a thymidine base 
at position -1 (the base before the TALE binding site). Although no sequence 
conservation exists between repeat units comprising the DNA binding domain and the 
amino acid sequence preceding the first repeat, secondary structure prediction studies 
indicate a degree of conservation in this -1 repeat[3]. TAL effector proteins also make 
contacts with the -1 T residue by a so called ‘0 repeat’ or ‘cryptic repeat’, present at the 
N-terminus of the central repeat domain. This interaction was found to be necessary for 
DNA binding and activation of target genes. The direct relationship between the identity 
of hypervariable residues (RVD) of repeat units and the sequence of TAL effector 
protein binding sites in host gene promoters enables the design of artificial TAL effector 
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proteins targeted to specific binding sites [3, 4]. The ability to assemble custom repeat 
arrays of TAL effector proteins that can bind desired DNA sequences has recently 
allowed for the design of artificial transcription factors and DNA binding domains with 
various functions[5-7].  
 
1.1.2 Crystal Structure of TAL Effector Proteins 
The final verification of the code governing TALE protein DNA binding came 
from crystallization studies in 2012 where two groups determined the atomic scale 
structure of two TALE proteins. The DNA binding domain of naturally occurring TAL 
effector protein PthXo1 from the rice pathogen X.oryzae was crystallized as bound to its 
DNA target (PDB:3UGM)[8]. In addition, crystal structure of an artificially engineered 
TAL effector protein, dHax3 was reported as both DNA-free and DNA-bound states 
(PDB: 3V6P and 3V6T, for DNA-free and DNA-bound structures, respectively)[9]. 
The structures in these studies, consistently show that repeat units of TAL 
effector proteins form a right handed, superhelical structure around a relatively 
unperturbed B-form DNA helix such that RVDs make contacts with residues in the 
DNA major groove (Figure 1.3). The external diameter for superhelical wrapping of the 
TAL effector protein around the DNA duplex is approximately 60 Ǻ. Each repeat unit 
corresponding to 34 amino acids in the primary sequence, consists of a left-handed helix 
bundle, in which a short and a long α helix are connected with a loop. In this structure, 
residues 3-11 of each repeat unit form the short α helix, whereas residues 14-33 form 
the long α helix, placing the 12th and 13th residues (the RVD) in the loop inserted into 
the DNA major groove. These structures identify a proline residue at 27th position of the 
repeats which generates a kink in the long helix, which is claimed to be critical for the 
sequential packaging of repeat units and the association of the tandem array of repeats 
with the DNA structure [8, 9]. The 13th residue in each RVD makes sequence specific 
contacts with target DNA; whereas, 12th residue interacts with a backbone carbonyl 
oxygen atom of a conserved alanine residue located at the C-terminus of each repeat. In 
other words, the first position of the RVD stabilizes the confirmation of the RVD loops 
rather than recognizing DNA and it is the second position (the 13th residue) of every 
repeat that contributes to the DNA binding specificity[8, 9]. 
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Figure 1.3 Crystal structure of the natural TAL Effector protein, PthXo1. a) Side view 
of PthXo1 in its DNA bound state and b) top view, the protein backbone is indicated in 
pink and the DNA double helix is shown in grey. c) Structure of a single repeat unit 
containing an HD RVD, the H residue is shown in red, the D residue in green and alpha 
helices in purple (PDB: 3UGM, [8]). 
The biochemical basis behind the sequence specific interaction of RVDs with 
DNA is clearly demonstrated by these two structural studies. In these structures, an HD 
RVD recognizes a cytosine base utilizing van der Waals interactions between an 
aspartate residue at the second position of the RVD with the cytosine and hydrogen 
bonds between a carboxylate oxygen atom of the aspartate and the N4 atom of cytosine. 
In these structures, an NG RVD interacts with a thymine base such that the smallest 
amino acid, glycine, at second position provides sufficient space for the 5-methyl group 
of the thymine base and forms van der Walls interactions with this methyl group.  In 
these structures, an NN RVDs interacts with less specificity, binding both adenosine 
and guanosine by forming a hydrogen bond between the second position asparagine and 
the N7 nitrogen of the adenosine and guanosine purine rings. The NS RVD is also 
nonselective because the second position serine makes hydrogen bonds with the N7 
atom of adenosine and guanosine purine rings. Curiously, these structural studies do not 
yield clues about contacts for interaction of the NS RVD with pyrimidines. Isoleucine, 
the second position residue of the NI RVD, forms non-polar van der Waals contacts 
between its aliphatic side chain and the C8 of adenine purine ring or the C5 of a 
cytosine pyrimidine ring [8, 9].  
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1.1.3 Designing Custom TAL Effector Proteins 
The simple and modular structure of the TAL effector DNA binding domain, 
enable the assembly of repeat units in a desired order resulting in specific recognition of 
target DNA sequence in any cell or organism. Designed arrays of TAL effector repeats 
have been fused to different functional domains to target these domains to desired 
genomic loci (Figure 1.4). Fusion of regulatory domains such as activators and 
repressors to TALE DNA binding domains can target these functions to desired gene 
loci in complex genomes [5, 10-12]. TALE repeat domain fusion to nonspecific 
nuclease domains is an important tool for site directed mutagenesis [5, 6]. Recently, the 
hyperactivated catalytic domain of the DNA invertase enzyme was fused to TALE 
DNA binding domains for constructing TAL effector recombinases (TALER) for site 
directed recombination [13]. 
 
Figure 1.4 TALE based custom proteins can be used to target DNA. Functional domains 
such as activators, repressors, nucleases and recombinases can be fused to the central 
DNA binding domain of TALE proteins for targeted modification of genomes. The 
TALE protein is shown fused to alternative C-terminal functional domains, the DNA 
binding domain comprising of TALE repeats are color coded as defined in Figure 1.1. 
An NLS is indicated by green stripes [2]. 
 The most common RVDs used in the assembly of TALE repeat arrays were NN, 
NI, NG and HD for the recognition of bases guanine, adenine, thymine and cytosine, 
respectively. However, the ability of NN RVDs to recognize both adenine and guanine 
is a drawback in designing TALE repeat arrays targeting DNA sequences containing 
guanine. TAL effector nucleases containing NK, a rare RVD among naturally occurring 
TAL effectors, for recognition of guanine was found to be less active than NN 
containing TAL effector nucleases. In addition, the affinity of NK containing TALE 
7 
 
repeat arrays to targets with guanine bases was found to be less than that of NN 
containing arrays[14]. In a recent study, the NH RVD was found to be more specific for 
recognizing guanine over adenine when compared to the other RVDs targeting guanine; 
NN and NK. Although NH may be a more specific guanine binder, the activity of 
TALEs with NH containing repeats was less than those with NN containing repeats [14, 
15]. Therefore, the current practice of designing artificial TALE proteins must take into 
consideration the affinity and specificity of individual repeats and often relies on 
empirically determined rules for binding. 
 
1.1.4 TALE Assembly Platforms 
The presence of multiple repeat sequences different only in two amino acid 
residues makes the assembly of custom TALEs using common molecular biology 
techniques, difficult. Although there are commercial DNA synthesis companies such as 
Cellectis Bioresearch and Life Technologies providing custom synthesized genes 
encoding TALEs[16], synthesis of highly repetitive sequences is complicated and 
currently too expensive for high-throughput genome editing experiments[2].  
An understanding of the features required for TAL effector protein activity has 
recently enabled the engineering of TAL effector protein coding genes using different 
assembly platforms, generated in three different laboratories: a)standard cloning-based 
methods, b) Golden Gate assembly methods and c) solid-phase assembly methods[17]. 
Standard cloning based methods assemble TALE repeat arrays through 
sequential restriction digestion and ligation of plasmids encoding units of single or 
multiple TALE repeat domains. Unit assembly [18], REAL (Restriction Enzyme and 
Ligation) [19] and REAL-Fast Assembly[20] are three reported methods using standard 
cloning assembly methods. Although the use of basic molecular cloning techniques 
seems like an advantage for these methods, it is not possible to perform high-throughput 
assembly. 
The Golden Gate assembly method uses type IIS restriction endonuclease 
enzymes, which generate multiple sticky ends of fragments that can be assembled in 
groups of up to 10 repeat unit fragments in the specified order in one single ligation 
reaction. Golden Gate assembly protocol takes approximately 5 consecutive days. This 
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assembly entails a two-step ligation reaction, where repeat units are first assembled in 
intermediary array plasmids and then joined in a final expression plasmid. Sequencing 
is performed for identification of the clone with correct number of repeat units. The 
Golden Gate assembly method is advantageous because of its simplicity, speed and low 
cost. As a result, this is the most popular TALE assembly method in published work [5, 
7, 10]. However, assembling large numbers of TAL effector repeat arrays is difficult 
using the Golden Gate method, making high throughput assembly not feasible. 
Currently, there are four different high-throughput TALE assembly methods 
based on solid phase assembly[2]. First, the FLASH (Fast Ligation-based Automatable 
Solid-phase High-throughput) system uses an archive of 376 plasmids encoding one, 
two, three and four TAL effector repeats with variously ordered RVDs that are 
assembled in an iterative fashion on solid phase magnetic beads. After assembly, the 
final TAL effector repeat array is released from magnetic beads by restriction enzyme 
digestion and cloned directly into an expression vector. Using this technique, 96 
different DNA fragments encoding the final full-length repeat array with the desired 
number of repeats can be assembled in less than one day [21]. The second protocol, 
iterative capped assembly (ICA) involves the addition of monomer units to growing 
chains of TALE repeats while blocking incomplete extension of chains using hairpin 
‘capping’ oligonucleotides. This method allows the synthesis of up to 21 repeat arrays 
in 3 hours [22]. The third technique, ligation independent cloning (LIC),is based on the 
use of a library of plasmids encoding repeat unit combinations containing long, unique 
single stranded DNA overhangs that anneal with overhangs of other fragments without 
any need for ligation. It is possible to construct plasmids encoding more than 600 
TALEs in a single day using the LIC strategy[12]. Finally a magnetic bead based TALE 
assembly method described by Wang et al. (2012), enables synthesis of over one 
hundred TALE repeat arrays with 16-20 units in three days[23]. 
Reagent kits for these different assembly platforms for TAL effector protein 
construction are currently provided by a non-profit plasmid distribution service 
Addgene (http://www.addgene.org/TALEN/). Software for designing arrays of TAL 
effector proteins, detailed protocols for plasmid construction, and reference collections 
are available on websites such as TALE-NT[24] and TALengineering.org[17]. An 
active and open newsgroup was established by the Joung research group at Harvard 
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Medical School, USA, for discussion of projects and problems related to TAL effector 
proteins (https://groups.google.com/group/talengineering).  
 
1.1.5 Targeted Genome Modification Using TALENs 
Designer nucleases are important tools for site directed mutagenesis at the 
genomic level. Genome editing by nucleases is not only a very useful tool for studying 
the function of targeted genes, but also has found spectacular success in the clinic for 
treating patients suffering from diseases caused by monogenic mutations. For treatment 
of HIV-1 infection, zinc finger nucleases (ZFNs) were designed to disrupt the CCR5 
(chemokine receptor 5) gene, which is a co-receptor required to infect T cells. 
Engraftment of ex vivo expanded HIV-1 resistant autologous CD4+ T cells resulted in 
lower viral count and higher CD4+ T-cell count in mice compared to wild-type CD4+ T 
cell engrafted mice[25]. The approach of using ZFNs in HIV treatment have entered 
Phase 2 clinical trials[17]. 
 ZFNs have traditionally been used as artificial (designed) nucleases. ZFNs 
contain a DNA binding domain composed of 3-4 synthetic zinc finger motifs fused to 
the non-sequence-specific DNA cleavage domain of the type II restriction enzyme FokI. 
The crystal structure of zinc finger transcription factors indicate that ZFNs bind DNA 
whereby each zinc finger motif recognizes a specific DNA sequence by inserting an α 
helix into the major groove of the DNA double helix[26]. In this structure, amino acids 
within each zinc finger motif make contacts with 4 bases of the DNA helix (3 on one 
strand and one on the opposite strand). Thus, a zinc finger DNA binding protein with 4 
motifs can contact up to 12 bases of DNA and zinc finger motifs can be modularly 
assembled to recognize long DNA sequences. 
The FokI restriction enzyme is a type IIS restriction endonuclease and 
dimerization of its endonuclease domain is required for its activity for creating double 
stranded DNA breaks. For this reason, ZFNs are designed to have two subunits resulting 
in the formation of a heterodimer on two closely oriented ‘inverted’ half sites. ZFN 
monomers bind to these two half-sites separated by a spacer region on which the FokI 
domain from each heterodimer assembles and generates a double stranded break 
(DSB)[27]. ZFNs have been used for genome modification of various model organisms. 
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However, generation of sequence-specific ZFNs is complicated, due to two main 
reasons. First, there exists a crosstalk between individual zinc finger motifs such that the 
motif in the second position affects the binding specificity of the motif in the first 
position, etc. This limits the modular use of  ZFNs for assembling designed DNA 
binding domains. In other words, the DNA binding of zinc finger nucleases is context-
dependent. Secondly, some zinc finger motifs are not specific to the targeted site, such 
that they can bind and cleave alternative sites, resulting in off target specificity. Because 
ZFNs are used to introduce DSB in genomic DNA that results in the generation of 
mutations, off target specificity may lead to unwanted mutations throughout the genome 
[28].  
 
Figure 1.5 TALEN structure for genome editing. For targeted genome modification, a 
pair of TALEs, each fused to a FokI DNA cleavage domain is designed to bind a target 
DNA sequence (black bases).The FokI enzyme requires dimerization for its DNA 
cleavage activity and assembles on the intervening spacer sequence (blue bases) to 
cleave in this region. TALEN enzymes have a modified structure compared to naturally 
occurring TALE proteins. The domain structure of TALEN proteins is as follows: the 
NLS (light green) is located at the N-terminus; N-terminal and C-terminal segments 
(orange) flank the DNA binding domain; the FokI domain (pink) is fused to the C-
terminus. Each repeat unit in the DBD is color coded (as in Figure 1.1) to indicate the 
RVD-DNA binding code [5, 29]. 
Transcription activator-like effector nucleases (TALENs) for targeted genome 
engineering (Figure 1.5) have generated much interest since the discovery of the one 
RVD to one base code [3, 4]. As in the case of zinc finger nucleases, TALENs consist 
of a DNA binding domain fused to a FokI restriction enzyme DNA cleavage domain. 
11 
 
Because FokI only cleaves DNA as a dimer, TALENs are designed as heterodimers, 
such that two monomers bind to individual target sites separated by a short spacer 
region. The length of the spacer region is important for FokI dimerization and DNA 
cleavage [30]. Several groups have used TALENs to modify endogenous genes in 
yeast[31], fruit flies[32], zebrafish[33-36], frogs[37], plants[7], livestock[38], mice[39] 
and human somatic and pluripotent stem cells[40] The simple one RVD to one base 
code makes the construction of TALE repeat arrays targeting any DNA sequence easy 
and routine. In a recent study, TALENs were found to be significantly more mutagenic 
than ZFNs [34]. In another study, side-by-side analysis of ZFNs and TALENs with 
overlapping binding sites for endogenous targets has shown that TALENs were less 
cytotoxic than ZFNs with similar gene disruption activities[41]. Lower toxicity is likely 
a result of lower rates of off target cleavage by TALENs when compared to ZFNs, 
which may result in unwanted mutation of alternative gene loci. These parameters make 
TALENs superior over ZFNs for targeted gene modification. 
 
1.1.6 Types of Genome Modification  
 Genome editing using site-specific nucleases depends on the generation of DNA 
double stranded breaks (DSB). Cellular repair of DNA DSBs induced at spacer regions 
occur either by non-homologous end joining (NHEJ) or if a homologous piece of DNA 
is present, by homologous recombination (HR) (Figure 1.6).  
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Figure 1.6 TALEN induced genome editing. Genome editing after DSB creation occurs 
either by non-homologous end joining (NHEJ) or by homologous recombination (HR). 
a) In the case of targeted genome editing using one TALEN pair, NHEJ results in small 
insertions and deletions (INDELs) at the site of the DSBs. HR can be used for gene 
deletion, gene insertion (for example an epitope tag) or gene replacement (for example a 
fluorescent reporter gene such as GFP) depending on the donor template used. b) If two 
TALEN pairs create DSBs on the same chromosome, NHEJ mediated repair may result 
in chromosomal deletion or inversion. If DSBs are generated on different chromosomes, 
translocations may occur. This mode of DNA repair may be problematic if off-target 
specificity is not minimized [2, 29]. 
NHEJ is an error-prone mechanism in which broken DNA ends are simply re-
joined leading to small insertions or deletions (INDELs) at the site of the double 
stranded break. INDELs induced in the protein coding sequences of genes will often 
yield frame-shift mutations leading to a knock out of gene function. Recently, it was 
reported that NHEJ mediated reading frame correction can be used to restore protein 
function in Duchenne muscular dystrophy, a genetic disease caused by mutations in the 
coding region for the dystrophin gene[42]. Homologous recombination repairs double 
stranded breaks using a homologous sequence as a template. In this case, a DNA 
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template with sequences homologous to those flanking the site of the double stranded 
break is introduced to the cell, together with TALEN encoding plasmids. Depending on 
the sequences within the donor template, homology directed repair can result in gene 
deletion, gene addition or gene replacement. Gene addition can be used to integrate 
specific genes under the control of specific promoter elements or to insert an epitope tag 
for labeling proteins encoded by endogenous genes. Gene replacement involves 
exchange of genetic information between an endogenous genomic region and an 
exogenous DNA template[2]. Use of single stranded homologous oligonucleotides as 
donors rather than a template plasmids was recently shown to be effective for homology 
directed repair of DNA double stranded breaks [35]. Introduction of two pairs of 
TALENs into cells at the same time may lead to more complex genome alterations. If 
two TALEN pairs target the same chromosome, this results in either large chromosomal 
deletions or inversions. On the other hand, targeting different chromosomes may lead to 
translocations[17]. In a recent study, large chromosomal deletions and inversions were 
obtained in livestock by targeting the same chromosome with two TALEN pairs [38].     
 
1.1.7 Scaffold Optimization 
Recent work has identified specific structural features of TAL effector proteins 
that are important in the construction of proteins with the desired specificity and 
activity. The main difference between various commonly available TALEN 
architectures is the length and sequence of the N-terminal and C-terminal amino acid 
sequences flanking the TALE DBD. In naturally occurring TALE proteins, the N-
terminal region contains sequences necessary for secretion into host plant cells. On the 
other hand, the C-terminal region contains both the nuclear localization signals and a 
transcriptional activation domain. In the earliest report of targeting DNA double 
stranded breaks with TAL effector-nuclease fusions, the DNA binding repeat domain 
was flanked by 287 amino acid N-terminal region and a 231 amino acid C-terminal 
region. This active TALEN protein pair recognized two 12 bp-long target sites on DNA 
separated by a spacer of 12-30 bp [30].  Even though this was the first of its kind to 
generate DSBs in genomic DNA, it was not known if the cutting efficiency or 
specificity was optimal and whether they could be improved. It is possible that amino 
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acid sequences flanking the DBD, necessary for TAL effector protein function in plant 
cells may interfere with the catalytic activity of TALENs.  
For this reason, several groups generated truncations in the N and C terminal 
regions of TALENs to optimize DNA cleavage activity. Miller et al. (2011) tested the 
activity of TALENs with different C-terminal linker lengths separating the DBD from 
the FokI catalytic domain. They found that TALENs with the highest activity contained 
a truncated 136 residue N-terminal and a 63 amino acid C-terminal domain. These 
truncated TALEN proteins resulted in a genome mutation rate between 5-20% across a 
spacer size range of 12-20 bp [6]. Another study determined that the minimal DNA 
binding domain of TALEN proteins must have at least 47 amino acids in the C-terminal 
linker between the TALE DBD and the FokI catalytic domain in addition to a truncated 
153 residue N-terminal domain. This study showed that these truncated TALEN 
proteins could cleave DNA with a spacer length of 12-21 bp between two target sites. 
An even shorter C-terminal linker with only 17 amino acids was also shown to be active 
when used for targeting 12 bp spacers[41]. These studies indicate that there is a 
correlation between the spacer length of the DNA sequence within which the FokI 
enzyme cleaves and the length of the C-terminal linker region separating the DBD from 
the FokI domain. This constraint likely affects the positioning of the two FokI 
enzymatic domains in a heterodimeric structure that is necessary for cleavage. 
A second generation TALEN scaffold named Goldy TALEN was recently 
reported to have improved genome editing efficiency in zebrafish [35]. Although the 
Goldy scaffold uses 136 residue N-terminal domain and a 63 amino acid C-terminal 
linker domain, like the previously described scaffold [6], there are nine different amino 
acid substitutions at the N-terminal and 5 different amino acids substitutions at C-
terminal linker domains. Efficient gene knockout was obtained in livestock using 
TALEN pairs assembled in a Goldy scaffold[38]. Recently, it was reported that DNA 
binding domains of 15 RVDs in the Goldy TALEN scaffold with spacers ranging 13-
19bp resulted in highly efficient genome editing in zebrafish[43]. 
 Various TALEN protein scaffolds optimize FokI domain dimerization to 
generate active TALEN heterodimers at target sites. However, optimizing the cleavage 
activity at a target site may also increase the probability of homodimeric TALEN 
proteins composed of identical subunits that bind to and cleave unwanted, ‘off-target’ 
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sites. Off target cleavage is a critical parameter for the efficacy and safety of designed 
TALEN pairs. In the case of ZFNs, off-target cleavage and the associated cytotoxicity 
were reduced using mutant FokI cleavage domains. Specific residues on the dimer 
interface of the FokI cleavage domain were mutated such that homodimerization of 
TALEN monomers were prevented by electrostatic and hydrophobic interactions [44]. 
The idea for mutant FokI cleavage domains to prevent homodimerization was 
successfully applied to TALEN proteins. In fact, obligate heterodimeric TALEN pairs 
induced similar or higher mutation frequencies in zebrafish genes when compared to 
TALENs with the same DNA binding domain with wild type FokI cleavage domains. 
Moreover, the frequency of abnormal embryos that developed after obligate 
heterodimeric TALEN pair encoding mRNA microinjection was less than that 
generated by mRNAs encoding homodimeric TALEN pairs, with wild type FokI 
domains[45]. Obligate heterodimer TALEN scaffolds were also used in studies that 
generated gene knockouts in zebrafish[36] and Xenopus embryos[37].  
 
1.1.8 Applications of Genome Editing Using TALENs 
TALENs have been used in various model organisms for targeted genome 
modification. In most of the studies, a single TALEN pair was used to induce NHEJ to 
create small insertions and deletions (INDELs) for generation of gene knockouts [21, 
32, 39, 42, 46]. Use of two TALEN pairs to create double stranded breaks on the same 
chromosome generates large chromosomal deletions and inversions [38]. Introduction 
of TALEN pairs together with a donor template, even a short single-stranded DNA 
allows insertion of a desired sequence into the target site [7, 35, 40]. In addition, 
homology directed repair of DNA double stranded breaks can be used for fusion of 
endogenous genes to sequences encoding epitope tags or fluorescent reporter proteins 
such as GFP to track protein expression, distribution and interaction with other proteins 
[17] (Figure 1.6). 
New animal models of human diseases can be rapidly created using TALENs to 
induce mutations without any need for embryonic stem cell cultures and targeting 
vectors. Recently, an animal model for familial hypercholesterolemia was created using 
TALENs targeting a gene that encodes low-density lipoprotein (LDL) receptor in 
livestock[38]. In a recent study, a phenotypic model of Hermansky-Pudlak syndrome, 
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which results in decreased pigmentation and bleeding problems, was created by 
injecting mRNAs encoding a TALEN pair together with synthetic 
oligodeoxynucleotides into one-cell stage mouse embryos to generate chocolate 
missense mutations in the RAB38 gene encoding a small GTPase for the regulation of 
intracellular vesicle trafficking. In this study, germline mutations created through 
homology directed repair of TALEN induced DSBs were corrected using a donor 
template with wild type sequence [47]. Thus, TALEN mediated gene modification has a 
great potential to be used in gene therapy to correct or disrupt genes or gene products, 
especially in the case of diseases with genetic components. 
Another use for TALEN technology is the generation of mutants for conducting 
structure-function studies probing the function of protein coding genes and genomic 
regulatory regions. In this study we generated TALENs to make mutations in a putative 
transcription factor binding sites in the enhancer of the IL7R gene and also we 
generated TALE proteins that competitively inhibit the important transcription factor 
NF-κB. The significance of these two TALEN targets is described in the section below. 
 
1.2 Interleukin-7 signaling 
1.2.1 Interleukin-7 and Interleukin-7 Receptor 
 Interleukin-7 (IL-7) is an essential and non-redundant cytokine necessary for the 
development, differentiation and survival of lymphocytes. The human IL-7 gene is 72kb 
long and is located on chromosome 8 encoding a protein of 20 kD, whereas the murine 
IL-7 gene is 41 kb in length and is located on chromosome 3, encoding a protein of 
about 18 kD. The active form of human IL-7 has a protein size of 25 kD due to post 
translational glycosylation. It is a single chain protein consisting of four α helices with a 
hydrophobic core. Human IL-7 is produced by nonhematopoietic cells, such as bone 
marrow stromal cells and epithelial cells of the thymus, skin and intestine[48, 49]. 
 
IL7 was discovered in 1988 as a result of its proliferative activity on immature 
murine B-cells in vivo. Later studies on IL-7-/- and IL7 receptor (IL7R)-/- knockout 
mice displayed a significant decrease in the number of T lymphocytes, indicating a role 
of the IL-7 cytokine in development. IL7 also has a role in maintaining stable numbers 
of naive and memory T-cells in the peripheral immune system. The proliferative effect 
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of IL7 on lymphocytes makes it a potent therapeutic for lymphoid regeneration in 
lymphopenic states such as after chemotherapy or radiotherapy (reviewed in [50]).   
 
IL7 signals lymphocytes by binding to its specific receptor IL-7R composed of a 
heterodimer of two transmembrane proteins: the specific α chain (IL7Rα, also known as 
CD127) and a common cytokine receptor γ chain (γc), which is shared by the receptors 
of IL-2, IL-4, IL-9 and IL-15. Both of these subunits are necessary for high affinity 
binding of IL-7. The human IL-7Rα gene is localized to chromosome 5 with a size of 
about 20kb whereas the murine IL-7Rα gene is on chromosome 15 with approximate 
size of 22 kb. Both human and murine genes contain eight exons and seven introns. The 
mature form of IL7R is composed of 439 amino acid residues with a molecular weight 
of 49.5 kD. IL7R is expressed mainly by lymphoid lineage cells, namely T-
lymphocytes, progenitor B-lymphocytes, and NK cells. IL7R is also expressed by cells 
of innate immune system such as certain dendritic cells, macrophages derived from 
bone-marrow and lymphoid tissue inducer cells (LTi).In addition, it was demonstrated 
that IL7Rα was present on non-hematopoietic cells such as human intestinal cells, 
human endothelial cells and several non-lymphoid cancer cells such as lung, melanoma, 
renal, colon and breast cancer cells [49, 51]. The role of this receptor on these non-
lymphoid lineages is currently not known. 
 
1.2.2 IL-7R Signaling Pathways 
 Extracellular IL-7 binding induces dimerization of the IL7Rα and γ chains. As a 
result, JAK kinases bound to the intracellular domains of the IL7Rα chain and γ chain 
are activated such that JAK3 phosphorylates JAK1 and the α-chain. Phosphorylated 
residues promote the recruitment of PI3K and STAT proteins. PI3K phosphorylates 
Akt, which promotes cell survival through degradation of pro-apoptotic proteins such as 
Bad and Bax. Phosphorylated STAT proteins dimerize and translocate to the nucleus 
and function as transcription factors that induce the expression of target genes such as 
Bcl-2, Cyclin D1, SOCS-1 and c-myc (Figure 1.7)[52].  
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Figure 1.7 The IL-7 receptor signaling pathway[52]. 
 
1.2.3 Importance of IL-7R Signaling for Lymphopoiesis 
 B cell development occurs mainly in the bone marrow and can be divided into 
different stages according to the expression of intra cellular and surface markers, 
rearrangement of status of the antibody encoding immunoglobulin heavy and light 
chains, and their cell cycle status[53]. Figure 1.8 shows the different stages of B cell 
development in the bone marrow and the expression of IL-7R in these stages. 
 The importance of the IL-7 response for mouse B cell development was 
demonstrated by a block in the transition from the pro-B cell to the pre-B cell stage in 
IL-7R deficient mice[54]. IL-7R signaling has a role in regulating the accessibility of 
chromosomes containing the immunoglobulin heavy chain genes to the gene 
recombination machinery during B lymphocyte development. Immunoglobulin gene 
recombination is important for the generation of the primary antibody repertoire 
diversity [55]. Attenuation of IL-7R signaling by the transcription factor IRF-4, 
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upregulated by pre-BCR signals, affects activation of light chain rearrangement in pre-B 
lymphocytes [56]. IL-7R signaling is necessary for expression of transcription factors 
such as EBF, important for transition from the pro-B stages to the more mature stages 
[57].  
 
Figure 1.8 IL-7R expression by lymphocytes[58].B lymphocytes of the bone 
marrowand T lymphocytes of the thymus express IL7R on the cell surface at different 
stages of development.The expression of IL7R is dynamically regulated during 
development. 
 
 IL-7R expression is tightly regulated in T cell development. It is expressed on 
double-negative thymocytes, absent on double-positive thymocytes and re-expressed by 
single positive cells (Figure 1.8). The double negative stage of T cells can be divided 
into four sub-populations according to the surface expression of CD44 and CD25, 
known as DN1 through DN4.β-selection of thymocytes occurs atthe DN3 stage. 
Developmental arrest of IL-7R deficient cells at the DN3 stage indicates that  IL-7 
signaling is essential for survival and proliferation of β-selected cells. In addition, 
absence of IL-7 signaling can be compensated by overexpression of anti-apoptotic 
proteins such as Bcl-2 or by loss of pro-apoptotic factors such as Bim or Bax (as 
reviewed in [59]). IL-7R signaling blocks the differentiation of DN cells to the DP stage 
by inhibiting expression of the transcription factors TCF-1, LEF-1 and RORγt [60]. 
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Thus, IL-7Rα expression is terminated in thymocytes that reach the double positive 
(DP) stage. IL-7Rα is re-expressed in post DP intermediate cells (CD4+CD8low)on 
which CD8 coreceptor transcription is selectively downregulated. Sustained TCR 
signaling results in differentiation of intermediate cells into CD4 single positive cells. 
Intermediate cells that no longer receive TCR signals differentiate into CD8 single 
positive cells as a result of  IL-7 signaling (as reviewed in [61]).Thus, IL7R signaling 
plays critical roles at different stages of T lymphocyte development and lack of 
signaling or misregulated signaling can cause diseases such as SCID or lymphoma[62, 
63]. 
In the peripheral immune system, IL-7Rα is expressed on all naive CD4 and 
CD8 T cells. Upon antigen stimulation of effector T cells, IL-7R expression is 
decreased whereas, paradoxically, receptor expression for other cytokines such as IL-2, 
IL-4 and IL-15 is increased. IL-7R expression is also upregulatedin memory cells. IL-
7R expression in naive and memory cells is important not only for their survival but 
also for maintaining a long term homeostatic balance between these peripheral 
cells[64]. 
 
1.2.4 Regulation of IL7R alpha Gene 
 The expression profile of IL7R changes during the different developmental 
stages of both B- and T-lymphocytes. Regulation of IL7R expression at these stages is 
controlled by different transcription factors that are tightly regulated during 
development. Various transcription factors that control IL7Rα expression at the 
transcriptional level have been identified. Figure 1.9 shows the IL7Rα gene locus and 
the bioinformatically identified transcription factor binding sites in this locus.   
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Figure 1.9 IL7R gene loci with different transcription factor binding sites 
 
 
 In the promoter region of the IL-7R gene, a GGAA motif serves as a binding site 
for PU.1 which is an ETS family transcription factor. It was demonstrated that PU.1 is 
required for IL-7R expression in developing B cells[65]. Although T cells do not 
express PU.1, this GGAA motif is occupied by another ETS family transcription factor, 
GGAA binding protein (GABP) that regulates IL-7R expression. GABP binding to the 
GGAA motif in the absence of PU.1 can promote IL7R expression in committed B 
cells, but not in early B cell progenitors[66]. 
 Runx1 is a transcription factor that regulates IL-7R expression and it has a 
binding site in promoter region of IL-7R gene. Studies on Runx1 deficient mice showed 
that this transcription factor was necessary for the positive selection and maturation of 
CD4 single positive thymocytes. It was suggested that the loss of survival signals due to 
an absence of IL7Rα expression in Runx1 deficient mice was the reason behind the 
reduction in the number of CD4 single positive T lymphocytes[67]. 
 The IL-7Rα gene locus has an evolutionarily conserved region (ECR) about 3 kb 
upstream of the transcription initiation site. This ECR contains binding sites for the 
GATA, Foxo, glucocorticoid receptor (GR) and NF-κB transcription factors. GATA-3 
is a zinc-finger transcription factor important in lymphocyte development. In addition to 
its role in T lymphocytes, GATA-3 and CD127 were found to be molecular markers for 
mouse thymic NK-cell development. Loss of CD127 expression on early thymocytes 
precursors in Gata3 deficient mice suggested that generation of CD127 positive NK 
cells is GATA-3 dependent[68]. 
 Foxo transcription factors, a subgroup of the Fork head family, have roles in the 
regulation of apoptosis, cell cycle progression, glucose metabolism and stress 
resistance. A Foxo binding site in the IL-7Rα gene is located about 3.5 kb upstream of 
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transcription initiation site according to detailed bioinformatics analysis. IL-7Rα 
expression in CD44lo CD4+ and CD8+ T cells was severely impaired in Foxo1 knockout 
mice, indicating a direct regulatory effect of Foxo1 on IL-7Rα transcription[69].Other 
transcription factors binding to enhancer region of IL-7R gene locus, Notch, NF-κB and 
GR whose binding sites were mutated in this study using TALEN technology, will be 
explained in detail below.   
 
1.2.4.1    Notch 
The Notch signaling is highly conserved in all metazoans with its roles in the 
regulation of cell proliferation, differentiation and cell death. The Notch receptor is a 
transmembrane protein and interacts with transmembrane ligands Delta and Serrate 
(Jagged in mammals) on neighboring cells. Binding of Notch to its ligand induces two 
proteolytic cleavages. The first cleavage by ADAM-family metalloproteases separates 
the extracellular domain of the receptor and the second cleavage driven by a γ-secretase 
enzyme complex releases the Notch intracellular domain (NICD) from the plasma 
membrane. NICD translocates to nucleus and interacts with the DNA binding protein 
CBF1/ RBPjk/ Su(H)/ Lag1 (CSL) and its co-activator Mastermind-like (MAML) to 
upregulate expression of target genes (Figure 1.10)[70, 71]. 
Notch signaling is important for T-lineage specification as demonstrated by 
studies in which induced deletion of Notch1 in hematopoietic progenitors resulted in a 
reduction in thymus size and a decrease in the number of thymocytes. In fact, the 
absence of Notch signaling in the thymus drives differentiation of lymphoid cells to the 
B cell lineage[72].  
Overexpression of the intracellular active form of Notch1 in human early thymic 
precursors (ETPs) in a fetal thymic organ culture (FTOC), upregulated IL7Rα 
expression whereas deficiency of Notch1 signaling resulted in the down-regulation of 
IL7Rα expression and a developmental arrest at the β-selection check point. In addition, 
a putative RBP-Jk-binding site was identified about 1000bp upstream of transcription 
initiation site of IL-7Rα after chromatin immunoprecipitation and luciferase assays 
showing IL7Rα is a direct transcriptional target of Notch1 [73].  
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Figure 1.10 Notch signaling [70].The Notch intracellular domain (NICD) is released 
from the membrane upon ligand binding induced cleavage of the Notch receptor on the 
plasma membrane. Cleaved NICD translocates into the nucleus and binds a preexisting 
CSL (RBP-Jk) transcription factor complex; helps recruit the adaptor protein 
Mastermind-like (MAML) and results in transcriptional activation. 
1.2.4.2 NF-κB 
 NF-κB is an important regulator in the immune system controlling the 
expression of numerous genes that are necessary in processes like cell survival, 
differentiation and proliferation. Tight regulation of the NF-κB pathway is important 
because its inappropriate activation is associated with different diseases such as cancer, 
autoimmunity and chronic inflammation. In the resting state, an NF-κB transcription 
factor composed of a heterodimer of the p50 and p65 proteins is bound to its inhibitor, 
IκB. The NFκB-IκB complex resides in the cytoplasm because of the shielding of the 
nuclear localization signal of NF-κB. Various external stimuli can activate NF-κB; three 
of them are summarized in Figure 1.11. Although various numbers of proteins are 
involved in each pathway initiated with different stimuli, all of them intersect in 
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activation of an IκB kinase, which phosphorylates IκB, leading to its ubiquitinylation 
and subsequent proteosomal degradation. Removal of IκB results in the activation of the 
NF-κB dimer which translocates to the nucleus and binds to its target sites for gene 
activation (as reviewed in [74, 75]).  
 An NF-κB binding site is present in the promoter region of the IL-7Rα gene. 
Whether this site has a functional significance for IL7R gene transcription has not been 
addressed. A microarray study linking NF-κB signaling to IL7R gene transcription 
identified IL7R as a TNF-inducible gene[76]. 
 
Figure 1.11 NF-κB signaling pathways. 
1.2.4.3 Glucocorticoid Receptor (GR) 
Glucocorticoids are secreted by cells of adrenal cortex as a response to the 
effects of cytokines released during inflammation such as TNF-α and IL-1β. 
Glucocorticoids act as anti-inflammatory factors by inhibiting cytokine mediated 
signaling pathways and inducing apoptosis in certain cells of the immune system [77].  
The glucocorticoid receptor, an inactive transcription factor resident in the 
cytoplasm of unstimulated cells is released from chaperones after binding its ligand, in 
glucocorticoid signaled cells and translocates to the nucleus. GR bound to its ligand can 
function by activating or inhibiting the transcription of various genes by binding to 
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glucocorticoid response elements (GRE) in their promoters (Figure 1.12). Another 
mechanism for transcription regulation of GR is protein-protein interaction. For 
instance, GR inhibits NF-κB regulated gene expression by binding to the p65 subunit of 
NF-κB to block the mechanistic interaction of p65 with the transcription machinery[78]. 
 
Figure 1.12 Glucocorticoid receptor signaling. In the absence of signaling, cytoplasmic 
GR (blue pentagon) is bound by the chaperones Hsp90 and p23. In the presence of the 
hydrophobic glucocorticoid ligand, which freely diffuses into the cell, GR dissociates 
from its chaperones, is phosphorylated and translocates into the nucleus. GR can 
activate genes with GRE elements, inhibit genes with nGRE elements and also inhibit 
NF-κB responsive genes by binding to the p65 subunit[77]. 
A GRE was identified 3000bp upstream of the IL-7Rα transcription initiation 
site. Recruitment of GR to this GRE activates transcription [79]. In a recent study, it 
was shown that both IL-7R mRNA and protein expression were upregulated in T cells 
treated with dexamethasone, a synthetic glucocorticoid [80]. 
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2. AIM OF THE STUDY 
 
 Transcription activator-like effector (TALE) proteins from the plant pathogen 
Xanthomonas have a central DNA binding domain (DBD) composed of highly 
conserved repeat units. These repeats are polymorphic at their 12th and 13th amino acid 
residues, named as repeat variable di-residues (RVDs) which determine the binding 
specificity of the DNA binding domain. A simple one RVD to one base code and the 
modular structure of the DBD allows for the engineering of TALE proteins with novel 
DNA binding specificity and functionality. TALE nucleases (TALENs) that consist of a 
non-sequence-specific FokI cleavage domain fused to a target site specific DNA 
binding domain are used for genome editing. Cellular repair of TALEN induced double 
stranded breaks (DSBs) occurs either by non-homologous end joining (NHEJ) or by 
homologous recombination (HR) that results in mutations at target sites.  
 In the first part of this study, we aimed to mutate transcription factor binding 
sites of the IL-7Rα gene locus using TALEN technology to determine the effects of 
these mutations on IL-7R expression. We designed and constructed three TALEN pairs 
targeting binding sites of glucocorticoid receptor (GR), Notch and NF-κB in the IL-7R 
gene enhancer. We performed a modified restriction fragment length polymorphism 
(RFLP) assay and DNA sequencing analysis to detect mutations induced at target sites 
of Neuro-2a and RLM11 cell lines transfected with TALEN constructs. We further 
analyzed the expression of IL-7R of mutated cell lines. In the second part of the study, 
we designed, constructed and expressed TALEdsRed fusion proteins binding to an NF-
κB binding site in a reporter cell line in order to inhibit the transcription activation 
function of NF-κB upon TNF-α treatment by competitive binding. The aim of this 
project in the long term is to generate novel cell lines with specific mutations. 
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3.  MATERIALS AND METHODS 
 
 
3.1 Materials 
 
3.1.1 Chemicals 
All the chemicals used in this project are listed in the Appendix A. 
 
3.1.2 Equipment 
All the equipment used in this project are listed in the Appendix B. 
 
3.1.3 Buffers and Solutions 
Standard buffers and solutions used in this project were prepared according to 
the protocols in Sambrook et al., 2001. 
Calcium Chloride (CaCl2) solution:  60 mM CaCl2, 15% glycerol and 10mM 
PIPES at pH 7.00 were mixed and the solution was filter-sterilized and stored at 4°C for 
competent cell preparation.  
5X Tris-Borate-EDTA (TBE) Buffer:  54 g Tris base, 27.5 g Boric acid and 
20mL of 0.5 M EDTA at pH 8.00 were dissolved in 1L of dH2O and stored at RT. 
 1% (w/v) Agarose gel: 1 g of agarose was dissolved in 100 mL of 0.5X TBE 
buffer by heating in a microwave oven. 0.001 % (v/v) of ethidium bromide was added 
to solution for visualization of nucleic acids.      
Phosphate-buffered saline (PBS) :  1 tablet of PBS was dissolved in 200 mL of 
dH2O. The solution was filter-sterilized for use in mammalian cell culture and stored at 
4°C.  
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Polyethylenimine (PEI) (1µg/µL):  50 mg PEI was dissolved in 50 mL dH2O 
that has been heated to ~80°C and cooled to room temperature. After neutralizing to pH 
7.00, the solution was filter-sterilized, aliquoted and stored at -20°C. 
 FACS buffer:   0.5 g Bovine serum albumin (BSA) and 0.5 g sodium azide were 
dissolved in 500 mL 1X HBSS and stored at 4°C.  
 
3.1.4 Growth Media 
3.1.4.1 Bacterial growth media 
Liquid media: 20 g Luria-Broth (LB) was dissolved in 1 L of dH2O and 
autoclaved at 121°C for 15 min. For selection, ampicillin with final concentration of 
100 µg/mL, kanamycin with final concentration of 50µg/mL, spectinomycin with final 
concentration of 50µg/mL and tetracycline with final concentration of 10µg/mL were 
added to liquid medium after autoclave.  
Solid media:  35 g LB agar was dissolved in 1 L of dH2O and autoclaved at 
121°C for 15 min.  For selection, antibiotics with previously indicated concentrations 
were added to autoclaved medium after cooling down to 50°C. Autoclaved and 
antibiotic added medium was poured onto sterile Petri dishes. Solid agar plates were 
stored at 4°C.  
 
3.1.4.2 Mammalian cell culture growth media 
Adherent cell lines Phoenix, NIH3T3, Neuro-2A, HEK293 6.1.1 were grown in 
DMEM cell culture medium that is supplemented with 10% heat inactivated fetal 
bovine serum (FBS),  2 mM L-glutamine,  100 unit/mL penicillin and 100 unit/mL 
streptomycin.     
Suspension cell line RLM11 were grown in RPMI 1640 cell culture medium that 
is supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mM L-
Glutamine,  100 unit/mL,  100 unit/mL streptomycin,  non-essential amino acids, 
vitamin and 50 µM 2-mercaptoethanol.  
Both adherent and suspension cell lines were frozen in fetal bovine serum (FBS) 
containing DMSO at a final concentration of 10% (v/v). Freezing medium is stored at 
4°C. 
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3.1.5 Cell Types 
E. coli DH-5α competent cells were used for bacterial transformation of 
plasmids. 
Neuro-2A mouse neuroblastoma cell line (ATCC: CCL-131) was used for 
transfection experiments. Phoenix cell line was derived from HEK293T cell line such 
that constructs for production of gag, pol and envelope protein were placed in that cells 
and used for virus production.  NIH 3T3 is mouse embryonic fibroblast cell line 
(ATCC: CCL-1658) and used for infection experiments. HEK293 6.1.1 is derived form 
of human embryonic kidney cell line such that 4 NF-κB binding sites fused with fos 
promoter and GFP were integrated to the genome. 
RLM11, a radiation-induced BALB/c murine CD4 single positive thymoma T 
cell line, was used for transfection and analysis of IL7R expression level with 
FACS[81]. 
 
3.1.6 Commercial Molecular Biology Kits 
 QIAGEN Plasmid Midi Kit,  12145, QIAGEN,  Germany 
 QIAquick Gel Extraction Kit,  28704, QIAGEN,  Germany 
 GenElute Mammalian Genomic DNA Miniprep Kit,  G1N350,  SIGMA, 
Germany 
 GenElute PCR Clean-Up Kit,  NA1020,  SIGMA, Germany  
 CloneJETTM PCR Cloning Kit, K1232, Thermo Fisher Scientific, 
 
3.1.7 Enzymes 
All enzymes and their corresponding buffers used in this project are from NEB 
and Fermentas.  
 
3.1.8 Vectors and Primers 
Vectors and primers used in this project are listed in Table 3.1 and Table 3.2.  
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Vector Name Purpose Bacterial Resistance 
pcDNA-GFP Transfection efficiency 
control 
Ampicillin 
pIRES2eGFP Cloning Kanamycin 
pMIGIIdsRED Cloning Ampicillin 
pcDNA3.1(+) Cloning Ampicillin 
pHD1-pHD10 
pNG1-pNG10 
pNN1-pNN10 
pNI1-pNI10 
Module plasmids for 
TALE / TALEN 
construction 
Tetracycline 
pFUS_A 
pFUS_B1- pFUSB10 
Array plasmids for 
TALE / TALEN 
construction 
Spectinomycin 
pLR-HD 
pLR-NG 
pLR-NN 
pLR-NI 
Last repeat plasmids for 
TALE / TALEN 
construction 
Tetracycline 
pCAG-T7-
TALEN(Sangamo) 
Backbone plasmid for 
TALEN construction 
Ampicillin 
pCAG-T7-
TALEN(Sangamo)-
FokI-KKR-Destination 
Backbone plasmid for 
TALEN construction 
with mutant FokI 
Ampicillin 
pCAG-T7-
TALEN(Sangamo)-
FokI-ELD-Destination 
Backbone plasmid for 
TALEN construction 
with mutant FokI 
Ampicillin 
pC-Goldy TALEN Backbone plasmid for 
TALEN construction 
Ampicillin 
pJET1.2/blunt Cloning of PCR 
products 
Ampicillin 
Table 3.1 List of vectors used in this project 
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Primer Name Sequence Purpose 
Notch for BamHI ATAGGATCCATTGAAACCATAACCACCCTC 
Notch TALEN 
target site 
amplification 
Notch rev Bgl2 GCGAGATCTCCCTTCTCTCTAATTCTGTT 
Notch TALEN 
target site 
amplification 
Kpl11 For CCAAGGAATAAACCCAAGGA 
NFKB TALEN 
target site 
amplification 
Kpl11 Rev TCTCCCAAGCAACAAAAGAA 
NFKB TALEN 
target site 
amplification 
pCR8_F1 TTGATGCCTGGCAGTTCCCT 
Colony PCR of 
Golden GATE 
reaction #1 
pCR8_R1 CGAACCGAACAGGCTTATGT 
Colony PCR of 
Golden GATE 
reaction #1 
TAL_F1 TTGGCGTCGGCAAACAGTGG 
Colony PCR of 
Golden GATE 
reaction #2 
TAL_R2 GGCGACGAGGTGGTCGTTGG 
Colony PCR of 
Golden GATE 
reaction #2 
SeqTALEN_ 
5-1 
CATCGCGCAATGCACTGAC 
Sequencing of final 
TALEN construct 
pJET1.2 forward 
sequencing primer CGACTCACTATAGGGAGAGCGCC 
Colony PCR and 
sequencing of 
cloned PCR 
products 
pJET1.2 reverse 
sequencing primer 
 
TTCTTGTAGCTAAAAGGTACCGTC 
Colony PCR and 
sequencing of 
cloned PCR 
products 
Table 3.2 List of primers used in this project 
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3.1.9 DNA Molecular Weight Marker  
DNA molecular weight marker used in this project is given in Appendix C. 
 
3.1.10 DNA sequencing 
DNA sequencing was commercially performed by McLab, CA, USA. 
(http://www.mclab.com/home.php) 
 
3.1.11 Software and Computer Based Programs 
The software and computer based programs used in this project  
Program Name Website/ Company Purpose 
CLC Main 
Workbench 
6.1.1 
http://www.clcbio.com/ 
Primer design, 
molecular 
cloning, 
sequence data 
management 
FlowJo 7.6.5 http://www.flowjo.com/ 
FACS data 
analysis 
TAL Effector 
Nucleotide 
Targeter 2.0 
https://tale-nt.cac.cornell.edu/ 
TALE / TALEN 
design tool 
Quantity One Bio – Rad 
Gel image 
analysis 
Visual 
Molecular 
Dynamics 
(VMD) 
http://www.ks.uiuc.edu/Research/vmd/ 
Crystal structure 
display and 
analysis 
Table 3.3 List of software and computer based programs used in this study 
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3.2 Methods 
 
3.2.1 Bacterial Cell Culture 
3.2.1.1 Bacterial culture growth  
E.coli DH5α bacterial cells were grown overnight (~16 h) at 37°C shaking at 
250 rpm in Luria Broth (LB). Bacterial cells were either spread or streaked on LB Agar 
plates to obtain single colonies and grown overnight (~16 h) at 37°C. Antibiotics were 
added to growth media depending on the application.  
For long-term storage of bacterial cells, glycerol was added to the overnight 
grown culture to a final concentration of 15% in 1 mL. Bacterial glycerol stocks were 
stored at -80°C.  
 
3.2.1.2 Competent cell preparation and transformation  
E. coli DH5α competent cells were prepared using stock of previously prepared 
competent cells. 50µL from previously prepared competent cells were grown in 50 mL 
LB without selective antibiotic overnight at 37°C shaking at 250 rpm. Next day, 4 mL 
from the overnight culture was diluted within 400 mL LB and incubated under same 
growth conditions until the OD590 reaches to 0.375. Then, previously prepared ice-cold 
CaCl2 solution was used for resuspension of bacterial cell pellet after successive 
centrifugation steps and for final preparation. 200µL aliquots of competent cells 
prepared were frozen immediately in liquid nitrogen and then stored at -80°C. 
Competency of prepared cells was tested by transforming varying concentrations of 
pUC19 plasmid.      
For transformation of competent cells, CaCl2 treated chemically competent 
bacterial cells were taken from -80°C and ~100 pg of plasmid DNA was added before 
cells were completely thawed. After 30 min of incubation on ice, the cells were heat-
shocked at 42°C for 90 seconds and transferred back to ice rapidly to chill for 60 
seconds. 800µL of sterile LB without antibiotics added and cultures were incubated for 
45 minutes at 37°C for recovery of cells and expression of antibiotic resistance gene 
encoded by the plasmid. Transformed cells were spread onto LB agar plates containing 
appropriate antibiotic for selection using sterile glass beads. Then, the plates were 
incubated overnight at 37°C. 
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3.2.1.3 Plasmid DNA isolation 
Plasmid DNA isolation was performed either by the alkaline lysis protocol or by 
QIAGEN Plasmid Midi Kits. For plasmid isolation, either single colony of E.coli from 
LB agar plates or glycerol stock was grown overnight at 37°C shaking at 250 rpm in 
liquid medium containing selective antibiotics with appropriate concentrations. The 
concentration and purity of kit-isolated plasmid DNA were determined using Nanodrop.   
 
3.2.2 Vector Construction 
Restriction Enzyme Digestion: Digestion reactions containing template DNA, 
enzyme and its compatible buffer were incubated at the optimum temperature of the 
enzyme used for 2 hours. ~ 300 ng of template DNA was used for diagnostic digestions 
whereas the amount of template DNA used for gel extraction and cloning purposes was 
at least 1 µg.  
Agarose Gel Electrophoresis and Gel Extraction: Agarose gels to observe DNA 
samples and digestion products were prepared in varying concentrations from 0.8% to 
2% depending on the size of DNA fragments to be separated. Agarose gel was prepared 
by dissolving appropriate amount of agarose powder in 0.5X TBE, heating for 3-5 min 
in a microwave. After cooling-down of the solution to room temperature, ethidium 
bromide was added at a final concentration of 0.001% (v/v) and the gel was poured onto 
the gel apparatus for solidification. 0.5X TBE was also used as running buffer. DNA 
samples were mixed with 6X DNA loading dye before loading to the gel. 
Electrophoresis was performed at 100-135 V for 45-75 minutes and the bands were 
observed under UV light. Gel extraction of DNA samples was performed by QIAGEN 
Gel Extraction Kit.  
Dephosphorylation of Vector Ends: 5’ phosphate groups of linearized vector 
DNA were dephosphorylated using Calf Intestinal Alkaline Phosphatase (CIAP) prior to 
insert ligation, to prevent vector re-ligation.  
Ligation:  Ligation was performed using T4 DNA Ligase (Fermentas), in 1:3 and 
1:6 molar vector to insert ratio using 100ng vector. In addition, ligation reaction mixture 
without insert was prepared as negative control for each ligation. The ligation reaction 
was incubated at 16°C for 16 hours in a final volume of 20µL. Then, half of the ligation 
mixture was transformed into chemically competent bacteria.  
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3.2.3 Construction of TALE Expression Plasmids  
3.2.3.1 Identification of TALE and TALEN target sites 
 The software used for design of transcription activator like effectors (TALE) 
and transcription activator like effector nucleases (TALEN) is available for use as an 
online tool (TAL Effector Targeter and TALEN Targeter (old version with design 
guidelines), TALE-NT; https://tale-nt.cac.cornell.edu/). DNA sequence entered is 
scanned for potential TALEN recognition sites based on either preset design guidelines 
defined by four different articles or user-provided spacer and RVD lengths. The 
software gives coordinates and sequences of recognition sites for right and left TALEN 
monomers and the spacer sequence. In addition, RVD sequences necessary for 
construction of custom TALENs were also provided as software output.  Binding sites 
of TALEN pair and spacer sequences are given in Table 3.4 
 
 
Left TALEN binding 
sequence 
Spacer 
Right TALEN 
binding sequence 
GR 
TALEN 
AGCACATGCTGTACCAAA
AT 
ATTATGTCTTAACTTAA
CTTTGTTCTTTTAC 
ATCTTCACAACTAAA
GG 
Notch 
TALEN 
AGGGTCACCCTCATA GACTCCTGGGAGTTTTC ATTGCCCTTGTTTCT 
NFKB 
TALEN 
TGCCCCACCCAAAAGGGG
TAA 
GCACACCAGTGGAAAT
CCCCTGAG 
CAAACTAGCACATGC
TGTA 
Table 3.4 Binding sites of TALEN pair and spacer sequences 
 
 3.2.3.2 Assembly of custom TAL Effector and TALEN constructs using 
Golden Gate TALEN kit  
 TAL effector DNA binding domain is composed of tandem repeat modules. 12th 
and 13th amino acids within each repeat module, called repeat-variable di-residues 
(RVDs), are responsible for nucleotide recognition. NI, NN, NG and HD are the four 
most common RVDs, each preferentially bind to nucleotides A, G, T, and C, 
respectively. Design of custom TALE and TALENs were performed using TALEN 
Golden Gate Kit, which was obtained from Addgene. The Golden Gate TALEN kit  was 
reported by Cermak et al (2011) and contains a set of module plasmids with each 
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individual RVDs, array plasmids for intermediate cloning and backbone expression 
plasmids to make final TALEN expression constructs[5].  
The custom TALEN or TAL effector construct is assembled by using successive 
rounds of Golden Gate cloning, in which digestion by Type IIS restriction 
endonucleases such as BsaI and Esp3I is performed to create unique 4 bp overhangs on 
DNA fragments. These unique overhangs flanking each RVD were designed such that 
up to 10 RVD-encoding repeat module plasmids can be ligated in a single reaction. 
Assembly of repeat modules into array plasmids is followed by assembly of array 
plasmids into final expression vectors (Figure 3.1).Construction of TAL effector or 
TALEN construct was achieved in 5 days (Figure 3.2) 
 
Figure 3.1 Golden Gate assembly of custom TALE and TALEN constructs 
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Figure 3.2 Timeline for TAL effector and TALEN construction using  
TALEN Golden Gate kit [5]. 
 
Day 1: After identification of possible TALEN target sites and determination of 
the RVD sequence, two separate array plasmids were assembled for “n” RVD repeat 
module containing TALEN expression plasmids. First 10 module plasmids selected 
according to the order of RVD sequence were cloned into array plasmid pFUS_A. Then, 
modules were selected for remaining RVDs, 11 – (n-1), and cloned into the array 
plasmid pFUS_B#n-1. RVD encoding modules for second array were selected starting 
with plasmid #1. Last RVD (#n) was not included in this reaction as it was provided by 
a different, “last repeat” plasmid and included in the second step of Golden Gate 
cloning. 
Golden gate reaction #1 was set according to Table 3.5 for each intermediary 
array plasmid, called as reaction A for first array plasmid and reaction B for the second 
one. For example a TALEN encoding plasmid with 17 repeats was generated by cloning 
10 repeats into the pFUS-A plasmid and 6 repeats into the pFUS-B6 plasmid. The 
contents of these plasmids were transferred in later days of the procedure into the pC-
Goldy TALEN destination expression plasmid along with the contents of LR plasmids, 
in a four plasmid reaction. 
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Components Used amount 
Each of module vectors 150 ng 
pFUS vector 150 ng 
BsaI (NEB) 1 µL 
BSA (2 mg/ ml) 1µL 
T4 DNA ligase (NEB) 1 µL 
10X DNA ligase buffer 2 µL 
dH2O Up to 20µL 
Total 20µL 
Table 3.5 Components and amounts for Golden Gate reaction #1 
Reactions were incubated in a thermo cycler for following cycle: 
10 X (37°C/5 min + 16°C/10 min) + 50°C/5 min + 80°C/5min  
 
In order to degrade unligated linear dsDNA fragments of incomplete ligation 
products, and linearized vectors, 1µL of exonuclease V (RecBCD) (NEB) and 1µL of 
10mM ATP were added to reaction and incubated at 37°C for 1 hour. 
Chemically competent DH5α E.coli cells were transformed with 2 µL of the 
reaction and plated on LB agar containing 50µg/mL spectinomycin, with X-gal and 
IPTG for blue/white screening of colonies.   
 
Day 2: Correct assembly of TALEN RVD repeat modules into intermediary 
arrays was controlled first by performing colony PCR with 5 white colonies picked 
from each plate. A PCR master mix was prepared according to colony PCR conditions 
shown in Table 3.6 using pCR8_F1 and pCR8_R1 as forward and reverse primers, 
respectively, individual colonies were resuspended in this solution.  
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Component Volume  
10X standard Taq 
buffer(Mg free) 
2.5µL 
25 mM MgCl2 2µL 
10mM dNTP each 0.5µL 
 Forward primer 0.2µL 
Reverse primer 0.2µL 
Taq polymerase (5U/µl) 0.125µL 
dH2O 19.475µL 
Total 25µL 
Table 3.6 Optimized colony PCR conditions 
PCR was performed according to following cycle; 
95°C/4 min + 30X (95°C/30 s + 55°C/30 s + 72°C/135 s) + 72°C/10 min  
 
Depending on the colony PCR results, two correct clones were inoculated into 
3mL LB containing 50µg/mL spectinomycin and incubated overnight at 37°C shaking 
at 200 rpm.  
 
Day 3: Plasmid DNA was isolated from overnight cultures of pFUS_A and 
pFUS_B plasmids containing repeats. Correct assembly of array was controlled by 
restriction enzyme digestion with AflII and XbaI and agarose gel electrophoresis. 
Double digestion with these enzymes releases the repeat arrays and size of fragments 
produced was 1048 bp for pFUS_A containing 10 RVDs whereas size of fragments 
varied for pFUS_B plasmids.   
Correctly assembled intermediary arrays and sequence encoding the nth repeat 
were assembled into the final expression backbone vector. TALEN Golden Gate Kit 
contains 4 different backbone plasmids, pTAL1 and pTAL2 for TAL effector design 
whereas pTAL3 and pTAL4 for TALEN construction and expression of designed 
TALEN in yeast.  For expression of TALENs in mammalian cells after assembly, 
different final expression plasmids obtained from Addgene which are pCAG-T7-
TALEN (Sangamo), pCAG-T7-TALEN (Sangamo)-FokI-KKR-Destination, pCAG-T7-
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TALEN (Sangamo)-FokI-ELD-Destination and pC-Goldy TALEN. For Golden Gate 
reaction# 2, digestion and ligation were performed in 2 steps due to BsmBI restriction 
enzyme working at 55°C which inhibited the activity of T4 DNA ligase. The first part 
of the reaction was set according to Table 3.7. 
 
Components Used amount 
Reaction A 150 ng 
Reaction B 150 ng 
pLR vector 150ng 
Expression backbone vector  75ng 
NEB Buffer 4 (10X) 1.5 µL 
BsmBI (NEB) 0.5 µL 
dH2O Up to 15µL 
Total 15µL 
Table 3.7 Components for the first part of Golden Gate reaction #2 
After incubation of the first part of the reaction at 55°C for 10 minutes, the 
second part of the reaction was set according to Table 3.8 
 
Components Used amount 
ATP (10 mM) 2 µL 
NEB Buffer 4 (10X) 0.5 µL 
T4 DNA ligase 1 µL 
DTT (0.2M) 1µL 
Water 0.5 µL 
Total 20 µL 
Table 3.8 Components for second part of Golden Gate reaction #2. 
 Reactions were incubated in a thermo-cycler using the following cycle: 
16°C /15min + 55°C / 15 min + 80°C / 5 min 
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Chemically competent DH5α E.coli cells were transformed with 2 µL of the 
reaction and plated on LB agar containing 100 µg/mL ampicillin, with X-gal and IPTG 
for blue/white screening of colonies.   
 
Day 4: Colony PCR was performed to check the assembly of intermediary arrays 
into the final expression plasmid and 5 white colonies were picked from the plate. The 
colony PCR mix was prepared according to Table 3, using TAL_F1 and TAL_R2 as 
forward and reverse primers. After resuspending individual colonies in a reaction 
mixture, colony PCR was performed according to the following cycle; 
95°C/4 min + 30X (95°C/30 s + 55°C/30 s + 72°C/3 min) + 72°C/10 min 
 
Depending on colony PCR results, two correct clones were inoculated into 3mL 
LB containing 100µg/mL ampicillin and incubated overnight at 37°C shaking at 200 
rpm. 
 
Day 5: Plasmid DNA was isolated from overnight cultures and correct assembly 
of the final full-length repeat array was verified by restriction enzyme digestion with 
AatII and StuI and agarose gel electrophoresis. In addition, BspEI control digest, which 
cut only in HD modules of 2-10, was performed to determine final array integrity. DNA 
midipreps were prepared from correctly assembled TALEN plasmids, and sequenced 
using the SeqTALEN 5-1 and TAL_R2 primers. 
 
To express TALEN pairs in mammalian cells, either TALEN constructs will be 
cloned to a plasmid containing mammalian expression promoter (Strategy 1) or the 
destination plasmid selected in Golden Gate reaction #2 would contain promoter for 
mammalian expression (Strategy 2). GR TALEN monomers that were commercially 
synthesized were cloned first to pMIGII backbone plasmids containing fluorescent 
reporter both to track expression of TALEN pair and to produce virus (Strategy 1a). GR 
TALEN pair was cloned to CMV promoter containing plasmids together with 
fluorescent reporters to express these plasmids ectopically in mammalian cells (Strategy 
1b). Two different TALEN pairs were designed using Golden Gate TALEN kit, 
TALEN pairs targeting Notch binding site and NF-κB binding site. After assembling 
repeat monomers in array plasmids of pFUS_A and pFUS_B, as destination vector 
either pCAGT7 (Strategy 2a) or pC-Goldy backbone were selected (Strategy 2c). In 
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addition, TALEN repeats constructed in pCAGT7 were cloned to PCAGT7-FokI-ELD 
or pCAGT7-FokI-KKR mutants (Strategy 2b). Figure 3.3 summarizes strategies of 
constructing TALEN pairs in different mammalian expression plasmid. 
 
 
Figure 3.3 Strategies for construction of TALENs in mammalian expression plasmids 
 
3.2.4 Mammalian Cell Culture 
3.2.4.1 Maintenance of mammalian cell lines 
Phoenix, NIH-3T3, Neuro-2A and HEK293 6.1.1 were adherent cell lines used 
in this project and were grown in DMEM cell culture medium that is supplemented with 
10% heat inactivated fetal bovine serum (FBS),  2 mM L-glutamine,  100 unit/mL 
penicillin and 100 unit/mL streptomycin in 10 cm tissue culture dishes. RLM11 was the 
only suspension cell line used in this project and was grown in RPMI 1640 cell culture 
medium that is supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 
mM L-Glutamine,  100 unit/mL,  100 unit/mL streptomycin,  non-essential amino acids, 
vitamin and 50 µM 2-mercaptoethanol in tissue culture flasks. All cultures were 
maintained in a humidified incubator supplied with 5% CO2 at 37°C and split into fresh 
medium when they reach to ~80% confluency. TALEN transfected cells were incubated 
in a humidified incubator supplied with 5% CO2 at 32°C after transfection for 72 hours. 
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For preparation of frozen stocks of both adherent and suspension cell lines, cells 
at exponential growth phase were resuspended in ice-cold freezing medium. They were 
stored at -80°C for 24-48 hours and then transferred to liquid nitrogen tank for long-
term storage. After thawing, cells were immediately washed with growth medium to 
remove any residual DMSO.   
 
3.2.4.2 Transient transfection of adherent cells with PEI 
Transient transfection of adherent cell lines was achieved using 
polyethylenimine (PEI). PEI is a cationic polymer, which forms complex with 
negatively charged DNA and bind to cell surface. DNA is taken into the cell via 
endosomal vesicles and osmotic swelling release plasmid DNA to the cytoplasm [ref. 
Pei]. One day before transfection, 4.0 x 106 adherent cells were split onto 10 cm tissue 
culture dishes. On the day of transfection, 7 µg of total DNA was diluted in 1 mL 
serum-free DMEM without phenol red in a sterile tube. PEI (1µg/µL) was added to 
diluted DNA based on 3:1 ratio of PEI (µg) to total plasmid DNA (µg) and mixed 
immediately by vortexing. After 15 minutes of incubation at room temperature, 
DNA/PEI mixture was added drop by drop on cells in tissue culture dishes. Viral 
supernatant from Phoenix cells was harvested twice as 24 hour and 48 hour after 
transfection. Viral supernatants were mixed, passed through 45-µm filters, aliquoted in 
1 mL and stored at -80°C.  Neuro-2A cells transfected with TALENs harvested 72 hours 
after transfection for FACS analysis. HEK293 6.1.1 cells transfected with TALE-dsRed 
constructs were treated with TNF-α approximately 38 hours after transfection and 
harvested 9 hours after that. 
3.2.4.3 Transient transfection of suspension cells 
Transient transfection of suspension cell line, RLM11, was done by using Neon 
electroporation system (Invitrogen). One day before transfection, cells were split 1:10 
ratio. 107 cells were washed twice with filter sterilized 1X PBS. After removal of 
supernatant, 10 µg DNA was added onto pellet and cells were resuspended in 100µL of 
HBS. Mixture was taken into 100µL Neon golden tips and placed in electroporation 
cuvette. Optimum transfection condition for delivery of DNA into cells is 1500 V with a 
single pulse in 20 miliseconds. Then, cells were transferred to tissue culture flasks 
containing pre-warmed RPMI supplemented with 10% FBS, 2 mM L-Glutamine, 100 
unit/mL,  100 unit/mL streptomycin,  non-essential amino acids, vitamin and 50 µM 2-
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mercaptoethanol. TALEN transfected RLM11 cells were incubated at 32°C-incubator 
supplied with 5% CO2 for 72 hours and harvested for further TALEN genotyping 
assays.  
3.2.4.4 Infection 
5 x 105 NIH3T3 cells were split for each well of 6-well plate one day before 
infection.  On the day of infection, viral supernatant was thawed and polybrene was 
added to a final concentration of 6 µg/ mL. After removing the supernatant of NIH3T3 
cells, viral supernatant containing polybrene was added onto cells and incubated for 2 
hours at 37°C. Then, medium was replaced with DMEM supplemented with 10% FBS,  
2 mM L-glutamine,  100 unit/mL penicillin and 100 unit/mL streptomycin. Virus 
treatment protocol was repeated in the next day. Cells were harvested for FACS 
analysis 48 hour after first virus treatment.  
3.2.4.5 Flow cytometric analysis  
106 cells were used for each flow cytometric analysis. Flow cytometric analysis 
of cells was performed using BD FACSCanto. For analysis of cells expressing 
fluorescent proteins GFP and dsRed, cells were washed twice with FACS buffer and 
resuspended in 500µL of FACS buffer for analysis. GFP and dsRed expression levels 
were detected with FITC and PE channels, respectively. For analysis of IL7R 
expression, cells were washed twice with FACS buffer and incubated with CD127-
Biotin antibody against mouse IL7Rα –Biotin at 4°C for 30 min in dark. After washing 
twice with FACS buffer to remove unbound antibody, cells were incubated with SA-
Alexa 647 at 4°C for 30 min in dark. Cells were washed twice with FACS buffer and 
resuspended 500µL of FACS buffer for analysis. IL7R expression levels were detected 
with Alexa-647 channel. 
 
3.2.5 TALEN Induced Mutation Screening 
 General strategy for detection of mutation at TALEN target site is given in 
Figure 3.4. In this study, mutation in TALEN target site was detected by loss of 
restriction enzyme cut site, restriction fragment length polymorphism (RFLP) assay.  
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Figure 3.4 General strategy for detection of TALEN induced mutation at target site.  
 
 In order to improve detection efficiency, RFLP assay was modified, which is 
summarized in Figure 3.5.  
 
Figure 3.5 Modified RFLP assay to increase mutation detection efficiency 
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3.2.5.1 Genomic DNA extraction 
72 hours after transfection with TALENs, genomic DNA of the cells was 
isolated by using GenElute Mammalian Genomic DNA Miniprep Kit (SIGMA). 
 
3.2.5.2 Restriction Fragment Length Polymorphism (RFLP) analysis 
Isolated genomic DNA was digested with enzyme in the spacer region, BsaJI 
and BstNI for TALENs targeting Notch binding site, and  BsrI for TALENs targeting 
NFKB binding site.  
PCR reaction was performed using digested genomic DNA according to 
optimized PCR conditions given in Table 3.9 using primers for TALEN target site 
amplification. 
Component Volume  
Template genomic DNA  1.0µL  
5X Phusion high fidelity 
buffer  
4.0µL 
10mM dNTP each 0.4µL 
 Forward primer (10mM) 1.0µL 
Reverse primer (10mM) 1.0µL 
Phusion Hot Start II DNA 
polymerase (2U/µl) 
0.2µL 
dH2O 12.4µL 
Total 20µL 
Table 3.9 Optimized PCR conditions for TALEN target site amplification 
 
PCR was performed according to following cycle; 
98°C/4 min + 30X (98°C/30 s + 64°C/30 s + 72°C/60 s) + 72°C/10 min  
 
PCR products were digested once again with the enzyme in spacer region and 
run on agarose gel to detect whether any undigested band is left indicating presence of 
mutation at TALEN target site.  
 
47 
 
Gel extraction was performed for the band in size of the undigested PCR 
product, and cloned using CloneJETTM PCR Cloning Kit (Thermo Scientific). Uncut 
bands were cloned to pJET1.2/blunt vector and colony PCR was performed to ensure 
presence of insert in selected colonies according to conditions provided by the kit. 
Plasmid DNA was isolated from 3-ml overnight cultures of true colonies and sequenced 
to evaluate mutations generated at cleavage site. 
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4. RESULTS 
 
 
4.1. Use of TALENs to Mutate Transcription Factor Binding Sites of the IL7R 
Gene 
In this study, we generated three pairs of TALENs to mutate transcription factor 
binding sites of the IL7R enhancer region (Figure 4.1). The first of these TALEN pairs 
targeted the GR binding site in the 3rd ECR of the IL7R gene were commercially 
designed and synthesized. The second and third TALEN pairs, targeting the Notch 
binding site and the NF-κB binding sites were assembled using the Golden Gate 
TALEN construction procedure explained in the Methods section. We hypothesized that 
IL7R expression would change because of a mutation in the binding sites of the 
transcription factors critical for its regulation. Thus, if GR, Notch or NF-κB plays a 
positive role in IL7R expression by binding to their respective sites in ECR3, cells 
mutated in these binding sites would decrease their levels of IL7R expression. 
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Figure 4.1 Schematic representation of the mouse IL7Rα gene locus. IL7Rα gene 
contains eight exons and three enhancer regions (ECR). ECR3 has binding sites for 
Gata, NFkB, GR and Foxo. Notch binds upstream region of ECR2. Three different 
TALEN pairs targeting the binding sites of the transcription factors GR, NFkB and 
Notch were designed in this study. Arrows indicate binding sites for primer pairs 
(Kpl11for-Kpl11rev and Notchfor-Notchrev) used for target site amplification. 
 
4.1.1 Commercially Designed GR TALEN Pair 
 A TALEN pair targeting the glucocorticoid receptor (GR) binding site of the 
IL7R enhancer region was commercially designed, synthesized and cloned in the 
pUC57 plasmid by Genescript Inc [http://www.genscript.com/].This TALEN pair was 
named GR TALEN, meaning TALEN targeting GR binding site. Figure 4.2 shows the 
binding sites of the commercially designed TALENs in theIL7R enhancer region 
together with the binding sites of various different transcription factors and primer 
binding sites used to analyze the region. 
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Figure 4.2 Binding sites of the commercially designed TALEN pair targeting the GR 
binding site of the IL7R enhancer region. Purple arrows indicate the left and right 
TALEN binding sites. Yellow arrow indicates the GR transcription factor binding site. 
Green arrows indicate the primer binding sites.  
 
 Because the pUC57 plasmid was not a eukaryotic expression plasmid, we first 
transferred the left and right TALEN coding sequences from this plasmid to a site 
upstream of the IRES-EGFP and the IRES-dsRed sequences respectively in the pMIGII 
retroviral mammalian expression plasmid backbone. Plasmid constructs were named 
pMIGII-GR left TALEN-IRES-eGFP and pMIGII-GR right TALEN-IRES-dsRed. Our 
reasoning for cloning TALENs into retroviral eukaryotic expression plasmids with 
fluorescent reporters were two fold. First, we wanted to track the expression of TALEN 
proteins with the expression of fluorescent reporter proteins. Secondly, we reasoned that 
upon retroviral infection, our expression cassette should be incorporated into the host 
cell genome and result in stable expression of TALEN mRNA. We surmised that high 
levels of TALEN protein expression would result inefficient cleavage of the target 
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sequence. It is well known that there are size limits for efficiently packaging large RNA 
molecules into retroviruses. The size of each constructed plasmid was around 10000 bp, 
which could limit production of virus from our expression plasmids. In addition, stable 
expression of TALEN proteins may result in over-expression which may increase the 
probability of generating off-target mutations. Therefore, we decided to transfer the 
TALEN sequences from the retrovirus plasmids to transient mammalian expression 
plasmids. The genes encoding TALENs targeting the GR site in the IL7R ECR3 were 
cloned downstream of a strong mammalian expression promoter, CMV, together with 
their fluorescent reporter proteins. These experiments are explained in detail below. 
 
4.1.1.1 Cloning of the left ECR3 GR binding site TALEN upstream of the eGFP in 
retroviral plasmid 
The strategy for cloning the left ECR3GR binding site TALEN upstream of the 
IRES-eGFP cassette in the pMIGII retroviral plasmid is shown in Figure 4.3. A DNA 
fragment containing TALE repeats was used to replace TcR αβ sequences in the 
pMIGII-TcR αβ eGFP plasmid (this plasmid was previously constructed in the Erman 
lab for an unrelated project). The plasmid constructed was named as pMIGII-GR left 
TALEN-IRES-eGFP. The use of an IRES-eGFP cassette resulted in TALEN mRNA 
expression from a bicistronic mRNA also encoding the eGFP fluorescence reporter. 
We digested the pUC57GR left TALEN plasmid with the BglII-EcoRI 
restriction enzymes, generating two bands of 4292 bp and 2641 bp. The 4292 bp-band, 
corresponding to the TALEN encoding sequence was extracted from an agarose gel. We 
digested the destination plasmid, pMIGIITcR αβ eGFPwith the BglII-MfeI restriction 
enzymes, generating two bands of 6316 bp and 1797 bp. The 6316 bp-band containing 
the retroviral vector backbone was gel extracted. The restriction enzymes MfeI and 
EcoRI generate sticky ends that are compatible with each other. Therefore, ligation of 
the 4292 bp-TALEN encoding fragment with sticky ends of EcoRI and BglII is 
possible.  
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Figure 4.3 Construction of the pMIGII left-GR TALEN IRESeGFP plasmid (Strategy 
1a). A flowchart for the cloning procedure is shown on the left, and gel electrophoresis 
images showing a representative diagnostic digest (using XhoI and BamHI-HindIII 
restriction enzymes). 
 
After determining the concentrations of gel extracted left GR TALEN encoding 
fragment and pMIGII vector backbone, we performed a ligation reaction using a 1:3 and 
1:6 vector:insert ratio, transformed these reactions into E.coli and isolated plasmid DNA 
from the formed colonies. We then performed a confirmation digest using the XhoI 
enzyme, which should generate two bands of 6322 bp and 4294 bp in the case of a 
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correct ligation. Next, we performed a BamHI- HindIII control digest for two of the 
colonies producing the expected bands in the previous XhoI digestion. The BamHI-
HindIII control digest should generate three bands of 5090 bp, 3550 bp and 1113 bp. 
The results of the confirmation digestions and a map of the constructed plasmid are 
shown in Figure 4.3.   
 
4.1.1.2 Cloning of the right ECR3 GR binding site TALEN upstream of the dsRed 
in retroviral plasmid  
The strategy for cloning the right ECR3 GR binding site TALEN upstream of 
the IRES-dsRed cassette in the pMIGII retroviral plasmid was given in Figure 4.4 and 
Figure 4.5. First, a DNA fragment containing TALE repeats was cloned into the pSP72 
plasmid, an intermediate vector to integrate the necessary restriction enzyme cut sites to 
the ends of this fragment. Then, the DNA fragment containing the TALEN repeats 
wascloned upstream of the dsRed sequence in the pMIGII-IRES-dsRed plasmid (This 
plasmid was previously constructed in the Erman lab for an unrelated project). The 
plasmid constructed was named pMIGII-GR right TALEN-IRES-dsRed. 
We digested the pUC57 GR right TALEN plasmid with BglII-HindIII restriction 
enzymes generating two bands of 3992 bp and 2635 bp. The 3992 bp-band, 
corresponding to right TALEN encoding sequence was extracted from an agarose gel. 
We digested pSP72 with BamHI-HindIII restriction enzymes which should generate 
fragments of 2432 bp and 30bp. The restriction enzymes BamHI and BglII generate 
sticky ends that are compatible with each other. The 2432 bp-fragment corresponding to 
vector backbone was extracted from an agarose gel. After ligation and plasmid DNA 
isolation, we performed a SacI digestion to control for correct integration, which should 
generate fragments of 3999 bp and 2433bp. As a second control, we digested this 
construct with the XhoI-BamHI enzymes, producing 4 bands of 3244 bp, 2432 bp, 641 
bp and 123 bp. An agarose gel showing these confirmation digestions of SacI and XhoI-
BamHI is shown in Figure 4.4. 
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Figure 4.4 Construction of the pSP72-right ECR3 GR binding site TALEN plasmid. 
 
We digested the intermediate pSP72-right ECR3 GR binding site TALEN 
plasmid construct with EcoRI, which should generate two bands of 4007 bp and 2417 
bp. The 4007 bp-band, containing right GR TALEN encoding sequence, was gel 
extracted. We linearized the pMIGII-IRES-dsRed plasmid with EcoRI and gel extracted 
the 6278 bp band. CIAP (Calf Intestine Alkaline Phosphatase) treatment was performed 
for the band to prevent vector re-ligation. 
We determined the concentrations of the gel extracted samples by agarose gel 
electrophoresis and accordingly, ligation reactions were set using 1:3 or 1:6 
vector:insert ratios. We digested the plasmid with SmaI to confirm the identity of this 
55 
 
plasmid, which should generate fragments with sizes of 5840 bp, 3422 bp and 1023 bp. 
An agarose gel showing the SmaI confirmation digest and plasmid maps are shown in 
Figure 4.5. 
 
Figure 4.5 Strategy for cloning the right ECR3 GR binding site TALEN from the pSP72 
plasmid upstream of the IRES-dsRed cassette in the pMIGII plasmid backbone 
(Strategy 1a). 
 
4.1.1.3 Stable expression of ECR3 GR binding site TALEN pair constructs in the 
NIH3T3 cell line 
We generated retrovirus from HEK293 Phoenix cells transfected with the 
[pMIGII-GR left TALEN-IRES-eGFP] and [pMIGII-GR right TALEN-IRES-dsRed] 
plasmids. Supernatants of transfected cells containing virus were used to infect mouse 
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NIH3T3 cells. In addition to TALEN constructs, we also generated virus from the 
pMIGIITcRαβ-IRESeGFP and pMIGII-IRESdsRed plasmids that were known to 
produce high titers of infectious virus as a positive control. Infection efficiency was 
determined by tracking eGFP and dsRed expression on a flow cytometer. Indeed we 
could not efficiently produce virus from these two plasmids to infect this cell line (data 
not shown). Although infection was successful for virus generated using the pMIGII 
backbone plasmid positive controls, we could not detect TALEN eGFP or 
TALENdsRed expression, indicating the infection was unsuccessful (Figure 4.6).The 
size of the TALEN plasmids could be the reason behind the low infection efficiency.For 
this reason, we decided to transfer these GR binding site TALEN reporter constructs 
into CMV promoter containing mammalian expression plasmids for transfection.  
 
Figure 4.6 Infection of NIH3T3 cells with virus produced using GR binding site 
TALEN fluorescence reporter plasmids. Dot-plots show relative eGFP fluorescence 
(labeled FITC on the x-axis) and dsRed fluorescence on the y-axis. From the top left, 
the four quadrants show GFP negative dsRed positive cells (Q1), GFP positive dsRed 
positive cells (Q2), GFP positive dsRed negative cells (Q3) and GFP negative dsRed 
negative cells (Q4).  
 
4.1.1.4 Cloning of the left ECR3 GR binding site TALEN into a CMV IRES eGFP 
mammalian expression plasmid 
The cloning strategy of the left ECR3 GR binding site TALEN into a CMV 
IRES eGFP mammalian expression plasmid is shown in Figure 4.7. The DNA fragment 
containing the left ECR3 GR TALEN in pUC57 was cloned into the pIRES2eGFP 
plasmid. The final plasmid construct was named CMV- left GR TALEN- IRES- eGFP. 
The pUC57-left GR TALEN plasmid was digested with EcoRI-BglII, generating 
bands of 4296 bp and 2645 bp. The 4296 bp-band, which corresponds to the left 
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TALEN encoding sequence was gel extracted. IRES2eGFP is a mammalian expression 
plasmid containing a CMV promoter before a multiple cloning site (MCS) and an IRES-
eGFP fluorescence reporter (Figure 4.7). It was digested with EcoRI-BglII which 
produces two bands of 5292 bp and 24 bp. The 5292-bp band corresponding to the 
vector backbone was extracted from an agarose gel. 
We isolated plasmid DNA from colonies formed after ligation and 
transformation. First, we performed a PstI control digestion which should generate 
bands of 5491 bp and 4097 bp. Second, we performed an XhoI-HindIII confirmation 
digest, producing bands of 5038 bp and 4550bp. Plasmid maps and agarose gels for the 
confirmation digestions of PstI and XhoI-HindIII are shown in Figure 4.7. 
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Figure 4.7 Strategy for cloning of the left ECR3 GR binding site TALEN downstream 
of CMV promoter and upstream of the IRES-eGFP cassette (Strategy 1b). 
 
4.1.1.5 Cloning of the right ECR3 GR binding site TALEN-IRES-dsRed cassette 
into a CMV promoter containing plasmid 
The strategy for cloning of the right ECR3 GR binding site TALEN IRES dsRed 
cassette from the pMIGII backbone to the pcDNA3.1 plasmid is shown in Figure 4.8. 
The final plasmid construct was named CMV-right ECR3 GR binding site TALEN 
IRES dsRed. We digested the pMIGII right GR binding site TALEN-IRES-dsRed 
plasmid with the SmaI-SalI restriction enzyme pair, which should generate four bands 
of 5300bp, 3422bp, 1023bp and 544bp. The 5300bp-band, corresponding to the right 
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GR binding site TALEN-IRES-dsRed cassette was extracted from an agarose gel. 
pcDNA3.1+ is a mammalian expression plasmid containing a CMV promoter upstream 
of a multiple cloning site. The destination plasmid pcDNA3.1+ was digested with the 
EcoRV-XhoI restriction enzyme pair, generating two bands of 5407 bp and 25 bp. The 
5407 bp vector backbone was gel extracted and ligated with the 5300 bp band 
corresponding to the right GR binding site TALEN-IRES-dsRed cassette. The size of 
final construct was 10703 bp. 
We transformed this ligation reaction into E.coli, isolated plasmid DNA from 
colonies and to confirm the identity of the plasmids, digested them with the EcoRI-
BglII restriction enzyme pair, producing three bands of 5766 bp, 4005 bp and 944 bp. 
Agarose gel images showing the EcoRI-BglII confirmation digest and plasmid maps are 
shown in Figure 4.8. 
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Figure 4.8 Strategy for cloning of the right GR binding site TALEN-IRES-dsRed 
cassette downstream of CMV promoter (Strategy 1b). 
 
4.1.1.6 Ectopic expression of the ECR3 GR binding site TALEN pair in Neuro-2a 
cells 
To express the TALEN pair targeting GR binding site, we co-transfected the 
[CMV left ECR3 GR binding site TALEN-IRES eGFP] and [CMV right ECR3 GR 
binding site TALEN-IRES dsRed] plasmids into Neuro-2a cells. 29.2% of cells were 
found to be both GFP and dsRed positive, indicating that both TALEN proteins could 
be expressed in these cells (Figure 4.9). Note that because both plasmids link the 
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TALEN sequences with the fluorescent reporter genes (GFP and dsRed) use an IRES 
element, the transcripts encoding the TALENs and the fluorescent proteins are bi-
cistronic. Thus the presence of the fluorescent protein in cells indicates the presence of 
the TALEN proteins. 
 
 
Figure 4.9 Transfection of murine Neuro-2a cells with CMV GR binding site TALEN 
fluorescence reporter plasmids. Dot-plots show relative eGFP fluorescence (labeled 
FITC on the x-axis) and dsRed fluorescence on the y-axis. From the top left, the four 
quadrants show GFP negative dsRed positive cells (Q1), GFP positive dsRed positive 
cells (Q2), GFP positive dsRed negative cells (Q3) and GFP negative dsRed negative 
cells (Q4).  
 
 We designed the TALEN plasmids targeting the GR binding site using the NK 
RVD to associate with G. During this study, Christian et al. (2012) found that NK RVD 
containing TALENs have lower affinity for G when compared with NN RVD 
containing TALENs[14]. In addition, the GR TALEN pair was designed to have a long 
C-terminal segment composed of 278 residues. However, a recent study conducted by 
Miller et al. (2011) indicates that efficient DNA cleavage is correlated with shortened 
C-terminal domains[6]. Also these TALENs were designed targeting a region that does 
not have appropriate restriction enzyme recognition sites in the genomic DNA. Thus, 
even if these TALENs were to cut genomic DNA at the target site and introduce 
mutations, we did not have an easy way to detect these mutations, such as the RFLP 
method described in detail in the following sections. For these reasons, we discontinued 
our work with the TALEN pair targeting the GR binding site in the IL7R gene. 
 
62 
 
4.1.2 Assembly of TALENs Targeting Notch Binding Site of IL7R Gene 
Using Golden Gate TALEN Kit   
 
4.1.2.1 Construction of a TALEN pair targeting the IL7R ECR2-ECR3 Notch 
binding site in the pCAGT7 backbone 
 
The TALEN design program TAL Effector Nucleotide Targeter 2.0 (https://tale-
nt.cac.cornell.edu/) was used to design a pair of TALENs targeting the Notch binding 
site in the region between ECR2 and ECR3 of the IL7R gene. The TALEN pair was 
selected from the output of the software such that both left and right TALENs contain 
15RVDs and the spacer region between the TALEN binding sites was 17 bp in length. 
Left and right TALEN binding sites were preceded by a 5’T base, in accordance with 
the TALEN design guidelines provided by the TAL Effector Nucleotide Targeter 2.0 
program. 
A custom TALEN pair targeting the IL7R Notch binding site was designed 
using the Golden Gate TALEN kit. As explained in detail in the Methods section, 
TALEN assembly using the Golden Gate TALEN kit takes 5 days and involves two 
main reactions for the assembly of individual repeat modules into array plasmids and 
assembly of array plasmids into a final mammalian expression plasmid. 
For the construction of the two 15 repeat long Notch binding site TALENs, we 
cloned the first 10 repeats into the pFUS_A plasmid and all remaining repeats except 
the last, into the pFUS_B4 plasmid (the Golden Gate reaction #1). Thus, we set up two 
Golden Gate reactions (reaction A and B) for each monomer of the TALEN pair. We 
transformed Golden Gate reaction #1 into E. coli, plated on IPTG/X-gal plates for blue-
white screening, performed colony PCR on white colonies using the primers pCR8_F1 
and pCR8_R1. Note that the number of colonies obtained after transformation was 
higher for the array vector containing less repeats than the ones with more repeats. For 
repeats in the pFUS_A plasmids, we detected bands around 1200 bp, whereas for the 
pFUS_B4 plasmids, we obtained around 600 bp bands. In addition to the band of 
expected size, a smear and ladder of bands were also detected which results from the 
presence of repeats in clones. After isolation of plasmid DNA from two correct 
colonies, we performed AflII-XbaI diagnostic digests which should generate bands 
reflecting the number of repeats such that a 1048bp-band was obtained for pFUS_A 
plasmid with 10 repeats whereas the band size was 430bp for the pFUS_B4 plasmids 
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with four repeats. Figure 4.10 and Figure 4.11 show agarose gel images after colony 
PCR with pCR8_F1 and pCR8_R1, confirmation with AflII-XbaI double digests and 
the plasmid maps related to reactions A and B of the left Notch binding site 
TALEN(Notch left TALEN) and the right Notch binding site TALEN (Notch right 
TALEN), respectively.   
 
Figure 4.10 Golden Gate reaction #1 for theleft Notch binding site TALEN 
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Figure 4.11 Golden Gate reaction #1 for the right Notch binding site TALEN 
 
In the Golden Gate reaction #2, we constructed an intermediary array of repeats 
coming from reaction A and reaction B, and the last repeat plasmid. We joined these 
three fragments in the final backbone plasmid, pCAGT7. We performed colony PCR 
using the TAL_F1 and TAL_R2 primers, which gave bands of 1744bp for the 15-
repeatsand a smear and ladder effect. A confirmation digest with AatII and StuI should 
result in the generation of a 1724bp-band, indicating the presence of 15 repeats. Figure 
4.12 shows agarose gel images after colony PCR with TAL_F1 and TAL_R2 primers, 
control digest with AatII-StuI and plasmid maps of both pCAG left Notch binding site 
TALEN and pCAG right Notch binding site TALEN. 
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Figure 4.12 Golden Gate reaction #2 for the Notch binding site TALEN 
constructs in pCAGT7 (Strategy 2a). 
 
4.1.2.2 Cloning of the designed Notch binding site TALEN monomers into mutant 
FokI destination vectors  
 Miller et al. (2007) claimed that the safety and efficacy of zinc finger nucleases 
(ZFNs), which are precursors of the TALENs which also use the dimerized FokI 
domain to cut DNA, was limited due to homodimerization rather than 
heterodimerization. This homodimerization resulted in off-target cleavage. Therefore, 
they engineered an improved ZFN architecture by mutating specific residues of the FokI 
enzyme dimerization interface such that they cleave target DNA only when monomers 
paired as heterodimers[44]. In the same manner, two mutant versions of pCAGT7 were 
developed by the group of Pawel Pelczar to improve TALEN efficiency.  pCAGT7-
FokI ELD includes the Q486E, I499L and N496D mutations of FokI whereas pCAGT7-
FokI KKR includes  the I538K, E490K, and H537R mutations. Therefore, to achieve 
efficient genome modification, we cloned the Notch left TALEN and Notch right 
TALEN constructs into the pCAGT7-FokI ELD and pCAGT7-FokI KKR plasmids 
respectively.  
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 To generate these plasmids, we digested the pCAGT7 Notch left TALEN 
plasmid with the BamHI-BglII restriction enzymes, generating two bands of 5418bp 
and 2119bp. The latter band was gel extracted. We digested the pCAGT7-FokI ELD 
plasmid with BamHI-BglII which gave two bands of 5414 bp and 1031 bp. The 5414 bp 
band was extracted from an agarose gel and ligated into the gel extracted pCAGT7 
Notch left TALEN fragment. Confirmation digests with ClaI-HincII restriction enzymes 
generated two bands of 7151 bp and 380 bp. Figure 4.13 shows the cloning strategy and 
the confirmation digest with ClaI-HincII for the pCAGT7Notch left FokI ELD plasmid. 
 
Figure 4.13 Cloning of the left Notch binding site TALEN into the pCAGT7 FokI ELD 
backbone (Strategy 2b). 
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To clone the right Notch binding site TALEN into the pCAGT7-FokI KKR 
plasmid, both pCAG Notch right TALEN and pCAGT7-FokI-KKR were digested with 
BamHI-BglII. Digestion of the pCAG Notch right TALEN plasmid with the BamHI-
BglII restriction enzyme pair generates two bands of 5418 bp and 2119 bp. The 2119 
bp-band corresponding to the Notch right TALEN repeats was gel extracted. The 
BamHI-BglII digestion of the pCAGT7 FokI KKR plasmid generated two bands of 
5414bp and 1031bp and the former one was gel extracted. Gel extracted bands were 
ligated and transformed. After isolation of plasmid DNA, we performed an XbaI-HincII 
confirmation digest, which generated bands of 5469 bp and 2064 bp. The cloning 
strategy and agarose gel image of the confirmation digest with XbaI-HincII is shown in 
Figure 4.14. 
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Figure 4.14 Cloning of the right Notch binding site TALEN construct to the pCAGT7 
FokI KKR plasmid (Strategy 2b). 
 
4.1.2.3 Construction of the TALEN pair targeting Notch binding site in the pC-
Goldy backbone 
 In a study conducted by Bedell et al (2012), it was shown that the DNA binding 
domain of a TALEN pair targeting the ponzr1 locus in the Goldy TALEN scaffold 
results in a six-fold increased somatic gene mutation rate when compared to the same 
DNA binding domain in the pTAL backbone[35]. Therefore, we decided from this point 
onwards to only use the pC-Goldy architecture to express TALENs. To transfer our 
TALENs into the pC-Goldy plasmid backbone, we repeated Golden Gate reaction #2 
for each monomer of the Notch binding site TALEN pair using the previously 
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constructed pFUS_A and pFUS_B array plasmids. We performed colony PCR with the 
TAL_F1 and TAL_R2 primers and observed the expected band size of 1745 bp along 
with a smear and ladder of smaller sized bands. An AatII -StuI confirmation digest of 
plasmid DNA extracted from these colonies generated five bands of 3863 bp, 1724 bp, 
1074 bp, 87 bp and 57 bp, of which the 1724 bp band reflects the number of repeats 
assembled, the other bands coming from the plasmid backbone. Agarose gel images 
showing the colony PCR and confirmation digest with the AatII-StuI enzymes and the 
maps of the plasmids with assembled repeats is shown in Figure 4.15. 
 
Figure 4.15 Golden Gate reaction #2 for the Notch binding site TALEN pair in the pC-
Goldy backbone (Strategy 2c) 
 
4.1.2.4 Expression of the designed Notch binding site TALEN pair in Neuro-2a 
cells and detection of site-specific mutations  
 We transfected the TALEN pair targeting Notch binding site in the pC-Goldy 
backbone into Neuro-2a cells. Although IL7R is only expressed on cells of the 
lymphoid lineage and these Neuro-2a cells are a cultured neuroblastoma line, we 
hypothesized that this would be an easy system to observe TALEN mediated mutations 
because of the high transfection efficiency of this cell line. The location of the binding 
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sites for the Notch TALEN pair, the forward and reverse primers used in amplifying the 
TALEN target site and the enzyme cut sites present in the spacer region are shown in 
Figure 4.16.  
 
Figure 4.16 Binding sites for the assembled TALEN pair targeting the Notch binding 
site of the IL7R enhancer region. Purple arrows indicate the left and right TALEN 
binding sites. Orange arrow indicates the Notch binding site. Green arrows indicate the 
primer binding sites. 
 
Our strategy for detecting site directed mutations was briefly summarized in the 
previous chapter (Figure 3.4 and 3.5). We attempted to detect mutations due to TALEN 
action by a restriction fragment length polymorphism (RFLP) assay with the BsaJI 
enzyme on PCR amplified target region DNA. In preliminary experiments from 
TALEN transfected cells, we could not detect an uncut band which is an indication of 
the presence of a mutated allele in this RFLP assay. For this reason, we modified our 
RFLP assay by first digesting genomic DNA with the BsaJI enzyme. We expected that 
BsaJI would only digest wild type alleles and that mutant alleles would remain uncut. 
We supposed that a PCR reaction with pre-cut genomic DNA would enrich mutant 
alleles allowing for better detection.  
The size of the PCR product from this region was 348 bp and after BsaJI digest, 
two fragments of 159 bp and 189 bp were generated from the wild type alleles. When 
the PCR product of the digested sample was digested with BsaJI, the presence of a 
BsaJI-resistant band indicated the presence of mutated alleles in the genomic DNA 
pool. The agarose gel image showing PCR products before and after BsaJI digestion for 
digested and undigested genomic DNA isolated from Neuro-2a cells is shown in Figure 
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4.17. We extracted the uncut band from these agarose gels and cloned this fragment into 
the pJET1.2/blunt vector for sequencing. We performed colony PCR for the colonies 
produced after transformation to control the presence of an insert in this plasmid. We 
screened more than 100 colonies by colony PCR and sequenced purified plasmid DNA 
from positive clones. 
 
Figure 4.17 Mutation detection at the Notch TALEN target site of Neuro-2a cells using 
a modified RFLP assay. Uncut PCR product indicating the presence of TALEN induced 
mutations is shown by a red arrow. 
  
 Sequencing analysis of mutations at the TALEN target site for 80 different 
colonies is shown in Figure 4.18. This result indicates that the Notch TALEN pair 
generated mutations at the target site of Neuro-2a cell genomic DNA, mediated through 
imprecise repair of chromosomal double strand breaks (DSB) by non-homologous end 
joining (NHEJ). Although it is not possible to detect the mutation frequency due to an 
enrichment step in our modified RFLP technique, we detected 14 different mutations 
including deletions ranging from 1-11 bp, insertions of 1-5 bp and one single base 
substitution. All of these mutations were centered on the spacer region between binding 
sites of TALEN monomers, containing and destroying the Notch binding site. 
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Figure 4.18 Site directed mutagenesis in Neuro-2a cells using the Notch binding site 
TALEN pair. Underlined regions of wild type sequence indicate the binding sites of 
TALEN monomers. Blue colored letters in the spacer region represent the Notch 
binding site, whereas the region highlighted in pink corresponds to the BsaJI cut site. 
Dashes indicate deletions. Red colored letters are SNPs and small case letters in red are 
insertions. Numbers on the right hand side indicates number of bases modified and 
frequency of occurrence of this mutation 
 
4.1.2.5 Expression of the designed Notch binding site TALEN pair in RLM11 cells 
and detection of site-specific mutations 
 We had designed the Notch TALEN pair to mutate the Notch binding site of the 
IL7R gene locus in order to study the functional significance of this site on IL7R 
expression. After demonstrating that our designed TALEN pair could indeed generate 
mutations in Neuro2a cells, we transfected the IL7R expressing RLM11 cells with our 
Notch TALEN pair in the pC-Goldy backbone.  
 Again, to detect site-specific mutations, we performed our modified RFLP assay 
(explained previously in Figure 4.16). An agarose gel image for BsaJI digests of PCR 
products from digested and undigested genomic DNA from TALEN transfected RLM11 
cells is shown in Figure 4.19. Again we gel extracted and cloned the uncut BsaJI-
resistant band into the pJET1.2/blunt vector for sequencing.  
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Figure 4.19 Mutation detection at the Notch TALEN target site of RLM11 cells using 
the modified RFLP assay. 
 
The result of our DNA sequencing analysis of target site mutation in TALEN 
transfected Rlm11 cells is shown in Figure 4.20. In this experiment, 27 different 
colonies were sequenced. As before, the use of an enrichment step for detecting 
mutations prevents the determination of the mutation frequency. Nevertheless, we 
detected 20 different mutations in this analysis including deletions ranging from 1 to 22 
bp, insertions of 1 bp, transitions and transversions.   
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Figure 4.20 Site directed mutagenesis in RLM11 cells using the Notch binding site 
TALEN pair. Underlined regions of the wild type sequence show the binding sites of 
the TALEN monomers. Blue colored letters in the spacer region represent the Notch 
binding site, whereas the region highlighted in pink corresponds to the BsaJI cut site. 
Dashes represent deletions. Red colored letters are SNPs and small case letters in red 
are insertions. Numbers on the right hand side indicates number of bases modified and 
frequency of occurrence of this mutation. 
  
4.1.2.6 Detection of mutations at the Notch binding site TALEN target site for 
different backbones  
 To observe whether the Notch binding site TALEN pair in different backbones 
results in a difference in terms of DSB generation and site directed mutation efficiency, 
we transfected the Notch binding site TALEN pair into RLM11 cells in the pCAGT7, 
pCAGT7 FokI ELD/KKR and pC-Goldy backbones. These plasmids encode left and 
right TALEN proteins that bind exactly to the same sequence but have minor 
differences in the C- and N-terminal regions of the TALEN proteins as well as 
differences in the FokI restriction enzyme domain. Moreover the promoter for the 
pCAG plasmids and the pC-Goldy are slightly different [35]. 
 We performed our modified RFLP assay for BstNI-digested genomic DNA 
isolated from these TALEN transfected cells. BstNI restriction enzyme digestion 
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generates two fragments of 188 bp and 161 bp from the wild type PCR product of 
348bp. Figure 4.21 shows the agarose gel image after BstNI digest of PCR products 
from BstNI digested genomic DNA. The intensity of the uncut band, indicating 
mutation efficiency, is the highest for the TALEN pair in the pC-Goldy backbone and 
the lowest in pCAG-FokI mutant ELD/KKR backbone.  This result is consistent with 
published results that show that TALENs in the pC-Goldy backbone are very efficient. 
 
Figure 4.21 Mutation detection at the Notch binding site of RLM11 cells using a Notch 
binding site TALEN pair in different backbones 
 
4.1.2.7 Expression of IL7R on RLM11 cells transfected with Notch binding site 
TALEN pairs 
 Although genomic DNA was isolated from a pool of RLM11 cells and an 
enrichment step was included in the detection of mutations at the TALEN site, it was 
important to observe the phenotypic effects of these mutations on IL7R expression. The 
IL7R expression level of RLM11 cells transfected with Notch TALENs in pC-Goldy 
backbone was analyzed by flow cytometry (FACS). We observed that Notch TALEN 
transfection did not result in a significant change in IL7R expression (Figure 4.22). 
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Figure 4.22 IL7R expression levels of untransfected and Notch TALEN transfected 
RLM11 cells. Histogram for Alexa-647 represents surface IL-7Rα expression. Solid 
black histogram shows expression profile of TALEN untransfected cells whereas dotted 
line shows Notch TALEN transfected cells 
 
 
4.1.3 Assembly of TALENs Targeting the NF-κB Binding Site of IL7R 
Using the Golden Gate TALEN Kit 
4.1.3.1 Construction of a TALEN pair targeting the IL7R ECR3 NF-κB binding 
site in the pCAGT7 backbone 
 A pair of TALENs targeting NF-κB binding site in the ECR3 region of IL7R 
was designed using TAL Effector Nuclease 2.0 software such that NF-κB left and right 
TALEN monomers consist of 20 and 18 RVDs, respectively and the spacer region 
between the TALEN binding sites is 24 bp in length.  
We performed Colony PCR using primers pCR8_F1 and pCR8_R1 for white 
colonies obtained after the transformation of Golden Gate reaction #1 into E.coli. For 
the first 10 repeats in pFUS_A plasmids, bands around 1200 bp were detected. The 
remaining repeats of the left NF-κB binding site TALEN were cloned into pFUS_B9, 
producing bands around 1100 bp, whereas the repeats for the right NF-κB binding site 
TALEN were cloned into the pFUS_B7 plasmid, generating bands around 900 bp after 
colony PCR. We performed AflII-XbaI control digests for the plasmid DNA isolated 
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from two colonies with the expected fragment sizes after colony PCR. AflII-XbaI digest 
yielded a 1048 bp-band for pFUS_A plasmids with ten repeats, a 920 bp-band for 
pFUS_B9 plasmids with nine repeats and a 720 bp band for the pFUS_B7 plasmid with 
seven repeats. Figure 4.23 and Figure 4.24 show agarose gel images of the colony PCR 
with the pCR8_F1 and pCR8_R1 primers, the confirmation digests with AflII-XbaI 
double digests and plasmid maps related to Golden Gate reactions A and B of left NF-
κB binding site TALEN (NF-κB left TALEN)and the right NF-κB binding site TALEN 
(NF-κB right TALEN), respectively.  
 
Figure 4.23 Golden Gate reaction#1 for the left NF-κB binding site TALEN 
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Figure 4.24 Golden Gate reaction#1 for the right NF-κB binding site TALEN 
  
 After joining intermediary array of repeats from reaction A and B, together with 
the last repeat plasmid to the pCAGT7 mammalian expression plasmid in a Golden Gate 
reaction #2, we performed colony PCR using the TAL_F1 and TAL_R2 primers. We 
obtained 2232 bp bands for the left NF-κB binding site TALEN construct with 20 
repeats and a 2028 bp band for the right NF-κB binding site TALEN construct with 18 
repeats. We also detected a smear and a ladder effect as expected, consistent with the 
published Golden Gate protocols. Confirmation digests with AatII and StuI resulted in a 
2234 bp- and 2030 bp-band for the NF-κB left and right TALENs, respectively. Figure 
4.25 shows agarose gel images after colony PCR with the TAL_F1 and TAL_R2 
primers, control digest with AatII-StuI and plasmid maps of both the pCAG left NF-κB 
binding site TALEN and the pCAG right NF-κB binding site TALEN.  
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Figure 4.25 Golden Gate reaction#2 for the left and right NF-κB binding site TALENs 
in the pCAGT7 backbone (Strategy 2a). 
 
4.1.3.2 Construction of a TALEN pair targeting the IL7R ECR3 NF-κB binding 
site in the pC-Goldy backbone 
 As before, during the course of this study, we realized that the pC-Goldy 
backbone generates better TALENs as compared to the pCAG-T7 backbone. Therefore 
we discontinued the use of our NF-κB site TALENs in the pCAG-T7 backbone and 
generated NF-κB site TALENs in the pC-Goldy backbone. To do this, we repeated 
Golden Gate reaction #2 for the left and right NF-κB binding site TALEN monomers 
using pC-Goldy TALEN as a backbone mammalian expression plasmid. Colony PCR 
with TAL_F1 and TAL_R2 primers produced the expected 2245 bp and 2041 bp bands 
for the left and right NF-κB binding site TALENs, respectively. AatII–StuI double 
digests of the pC-Goldy left NF-κB binding site TALEN generated five bands of 3863 
bp, 2234 bp, 1074 bp, 87 bp and 57 bp, of which the 2234 bp-band reflects the number 
of repeats assembled. The 2030 bp-band after confirmation digest of pC-Goldy right 
NF-κB binding site TALEN indicates the assembly of 18 repeats. Agarose gel images 
showing the colony PCR, the AatII-StuI confirmation digest and plasmid maps of pC-
Goldy left and right NF-κB binding site TALEN plasmids is shown in Figure 4.26. 
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Figure 4.26 Golden Gate reaction#2 for the left and right NF-κB binding site TALENs 
in the pC-Goldy backbone (Strategy 2c) 
 
4.1.3.3 Expression of the designed NF-κB binding site TALEN pairs in RLM11 
cells and detection of site-specific mutations 
We transfected RLM11 cells with NF-κB binding site TALEN pairs in the pC-
Goldy backbone for ectopic expression which would result in mutation at NF-κB 
binding site of the IL7R gene locus. We performed our modified restriction fragment 
length polymorphism (RFLP) assay to detect mutations at the target site. Figure 4.27 
shows the locations of the binding sites of NF-κB binding site TALEN pair, the forward 
and reverse primers for amplification of the target site, and the restriction enzyme cut 
sites present in the spacer region.  
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Figure 4.27 Binding site of the assembled TALEN pair targeting the NF-κB binding site 
of the IL7R enhancer region. Purple arrows indicate the left and right TALEN binding 
sites. Red arrow indicates the NF-κB binding site. Green arrows indicate the primer 
binding sites. 
 
We digested a 777 bp PCR products of BsrI digested and undigested genomic 
DNA with BsrI to determine the presence of mutated alleles in the pool of NF-κB 
binding site TALEN transfected cells. Wild type PCR products generated of 421 bp 336 
bp fragments after BsrI digestion (Figure 4.28). We extracted the uncut band and cloned 
it into the pJET1.2/blunt vector for sequencing. 
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Figure 4.28 Mutation detection at NF-κB TALEN target site of RLM11 cells using 
modified RFLP assay 
 
 Sequencing results for 40 different colonies reveal the presence of 4 different 
mutations (Figure 4.29). Three of these contain a deletion of 15 bp. Moreover, transition 
and transversion mutations were detected in all mutants sequenced except one. Note that 
the NF-κB binding site was not mutated in any of the mutants sequenced.  
 
 
Figure 4.29 Site directed mutagenesis in RLM11 cells transfected with TALEN pair 
targeting NF-κB binding site. Blue color in wild type sequence indicates NF-κB binding 
site and underlined sequence represent binding sites of TALEN monomers. BsrI cut site 
is highlighted in pink. Dashes indicate deletions whereas red colored bases are for 
SNPs. Numbers at right-hand side gives number of bases deleted and occurrence of this 
mutation, respectively.   
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4.1.3.4 Expression of IL7R on RLM11 cells transfected with NF-κB binding site 
TALEN pairs 
Although the NF-κB site was not mutated in any of the sequenced mutants, we 
nevertheless decided to assess IL7R expression in these mutant RLM11 cells. We 
hypothesized that the large 15bp deletion would result in a block of enhancer activity 
and that we would observe a decrease in IL7R expression in these mutant cell 
containing pools of RLM11 cells. As before we assessed IL7R levels by FACS and 
found that expression of these surface proteins was less in mutant cell pools than that of 
untransfected RLM11 cells (Figure 4.30). 
 
Figure 4.30 IL7R expression levels of untransfected and NFKB TALEN transfected 
Rlm11 cells. Alexa 647 mean shows the relative IL7R expression on the cell surface. 
Solid black line shows the expression profile TALEN untransfected cells whereas 
dotted line shows of NF-κB TALEN transfected cells. 
 
4.2 Use of TALE as Competitive Inhibitors 
TNFα treatment results in phosphorylation and subsequent ubiquitinylation of 
IkB. Degradation of IκB activates the NF-κB complex resulting in translocation to the 
nucleus. A reporter plasmid containing four NF-κB binding sites upstream of fos 
promoter and GFP sequence was constructed by Pınar Onal (2007) in the Erman Lab. 
Induction of cells transfected with the 4κB GFP constructs with TNFα results in the 
production of GFP due to the binding of nuclear translocated NF-κB upstream of the 
GFP gene. The 4XNF-κB binding site-fos-GFP cassette was stably integrated into the 
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genome of HEK293 cells by Belkıs Atasever Arslan, in the Erman Lab and this reporter 
cell line was named HEK293 6.1.1.  
TALE DNA binding domains were constructed to competitively inhibit NF-κB 
binding to DNA. We hypothesized that expression of TALE proteins in reporter cells 
would inhibit the binding of nuclear translocated NF-κB to its binding sites in this 
reporter, after TNFα induction. Our expectation was that the level of GFP expression 
upon TNF treatment in cells transfected with TALE proteins would be lower than in 
untransfected reporter cells (Figure 4.31). We designed this system by fusing the TALE 
proteins to a fluorescent protein, dsRed, in order to track transfected cells.  
 
 
Figure 4.31 Strategy of designing TALEdsRed constructs as competitive inhibitors. 
TNFα treatment of HEK293 6.1.1 cells, containing stably integrated 4X kappaB binding 
site upstream of a fos promoter and GFP, results in GFP expression whereas 
TALEdsRed expression in these cells is expected to inhibit GFP expression.  
 
4.2.1 Construction of pCAGdsRed Plasmid 
 To construct TALEdsRed competitive inhibitors, the cloning strategy for 
backbone plasmid generation was designed such that dsRed in the pBluescript-dsRed 
plasmid (Plasmid was previously constructed in Erman Lab for an unrelated project.) 
was replaced with in the pCAGT7 plasmid (Figure 4.32).  
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 We digested the pCAGT7 plasmid with BamHI, blunted using the Klenow 
enzyme and digested with SacI, which should generate fragments of 5845bp and 604bp. 
The 5845bp fragment corresponding to the plasmid backbone was gel extracted. The 
pBluescript-dsRed plasmid was digested with the SmaI-SacI restriction enzyme pair, 
producing bands with sizes of 2921bp and 752bp. The 752bp-band corresponding to 
dsRed sequence was gel extracted. SmaI generates blunt-ended fragments, making 
ligation to the fragment blunted after BamHI digest possible. After ligation, NotI 
confirmation digest was performed for the plasmid DNA extracted from colonies. NotI 
digestion should generate bands of 6267 bp and 330 bp for correctly ligated plasmid 
DNA. As a second control, PstI-Bgl2 double digestion was performed, producing three 
bands of 5177 bp, 1219 bp and 205 bp. Figure 4.32 shows agarose gel images of 
confirmation digests and a map of the constructed plasmid. 
 
Figure 4.32 Cloning strategy for construction of the backbone plasmid with a 
fluorescent reporter, pCAGdsRed.  
 
4.2.2 Golden Gate TALE Assembly of the Competitive Inhibitors of NF-κB 
Binding Using the pCAGdsRed Plasmid as Backbone Vector   
Six different TALEdsRed constructs that have specificities to bind to NFkB 
binding sites were designed using the Golden Gate TALEN kit. The number of repeats 
range from 12 to 17 such that the first 12 RVDs were same in all constructs. Therefore, 
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in the Golden Gate reaction#1 only one pFUS_A plasmid containing repeat was 
constructed for all six TALEdsRed constructs and different pFUS_B plasmids were 
generated for each. Colony PCR was performed for white colonies obtained after 
transformation of reaction#1 using primer pair pCR8_F1 and pCR8_R1. For repeats in 
pFUS_A plasmids, bands around 1200 bp were detected whereas for each pFUS_B 
plasmids, band sizes changed from 350 bp to 820 bp according to the number of repeats 
in that array plasmid. AflII-XbaI confirmation digest was performed for colonies 
producing expected bands after colony PCR. A 1048 bp-band was obtained for pFUS_A 
plasmid with 10 repeats. Bands from 147 bp to 622 bp were obtained for the NF-κB 
reporter B1 to NF-κB reporter B6, with sizes increasing approximately 100 bp for each 
repeat. Figure 4.33 and 4.34 show agarose gel images after colony PCR with pCR8_F1 
and pCR8_R1, confirmation digest with AflII-XbaI and plasmid maps of reaction A and 
reaction B of TALEdsRed constructs.  
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Figure 4.33 Golden Gate reaction#1 for NF-κB reporter A, B6, B5 and B4 plasmids. 
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Figure 4.34 Golden Gate reaction#1 for NF-κB reporter B1, B2 and B3 plasmids. 
 
For construction of each TALEdsRed plasmid, a pFUS_A plasmid together with 
a pFUS_B plasmid with corresponding repeats and the last repeat plasmid were joined 
to the pCAGT7dsRed final expression plasmid in the Golden Gate reaction #2. Colony 
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PCR was performed for colonies obtained after transformation using pTAL_F1 and 
pTAL_R2. The size of bands obtained after colony PCR ranged from 1400 bp to 1900 
bp for plasmids TALEdsRed12 to TALEdsRed17 such that one repeat increases the size 
100 bp. Confirmation digest with AatII-StuI enzyme pair was performed for colonies 
generating expected band sizes. The size of the bands obtained after digestion was the 
same with that obtained after colony PCR. Agarose gel images related to colony PCR 
and confirmation digests, and plasmid maps of the final TALEdsRed constructs are 
shown in Figure 4.35, 4.36 and 4.37. 
Figure 4.35 Golden Gate reaction #2 for TALEdsRed12 and TALEdsRed13 plasmid 
construction. 
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Figure 4.36 Golden Gate reaction #2 for TALEdsRed14 and TALEdsRed15 
construction. 
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Figure 4.37 Golden Gate reaction #2 for the TALEdsRed16 and the TALEdsRed17 
construction. 
 
4.2.3 Expression of TALE-dsRed Constructs in HEK293 6.1.1 Cells and the Effect 
on GFP Expression 
 To determine whether expression of TALE dsRed constructs affects GFP 
expression in HEK293 6.1.1 cells upon TNFα treatment, designed TALEdsRed 
constructs were transfected to these cells and TNFα treatment was performed 
approximately 9 hours before FACS analysis. Figure 4.38 shows the net GFP 
fluorescence means of cells transfected with TALEdsRed constructs. The DsRed 
positive population of all NF-κB transfected cells has a lower GFP fluorescence mean 
than that of the untransfected samples.   
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Figure 4.38 GFP expressions of TALEdsRed transfected HEK293 6.1.1 cells after 
TNFα treatment. y-axis shows net GFP fluorescence mean. Green bars show the net 
GFP mean for dsRed negative cells and red bars show the net GFP mean for dsRed 
positive cells. ut: untransfected. 
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5. DISCUSSION  
 
 Transcription activator-like effector (TALE) proteins are recently described 
DNA binding proteins, isolated from the plant pathogen Xanthomonas[1]. The DNA 
binding domain of TALE proteins is composed of 34 amino acid long repeat units 
where the12th and 13th residues (repeat variable di-residues, RVDs) of each repeat 
determine the binding specificity of the protein[3, 4]. A simple one RVD to one base 
code and the modularity of repeat arrays enable researchers to construct TAL effector 
proteins to bind desired DNA sequences. Fusion of the TALE DNA binding domain to 
the catalytic domain of the FokI restriction enzyme makes them an efficient tool for 
genome engineering as site-directed nucleases[5, 6].  
 Interleukin-7 signaling is crucial for development, differentiation and survival of 
lymphocytes. The expression of IL-7Rα on lymphocytes changes during their 
development. Upstream promoter and enhancer regions of the IL-7Rα gene locus 
contain binding sites for transcription factors that have roles in regulating this 
expression[66, 68, 69, 73]. In order to understand the roles of these transcription factors 
in the regulation of IL-7Rα gene expression in lymphocytes, we mutated the binding 
sites of three transcription factors; namely, glucocorticoid receptor (GR), Notch and 
NF-κB, using TALEN technology. In addition, we constructed TALE-dsRed fusion 
proteins that competitively bind in place of NF-κB. 
 Our first TALEN pair, targeting the GR binding site of the IL-7Rα gene locus 
was synthesized and purchased from a company. We cloned both the forward and 
reverse TALEN monomers into a retroviral vector backbone encoding fluorescent 
reporter proteins to create stable cell lines expressing the TALEN pair after infection. 
These retroviral constructs utilized internal ribosome entry site (IRES) elements 
between the TALEN cDNA and the fluorescent protein encoding genes. This enabled us 
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to express TALEN monomers and fluorescent marker proteins (eGFP and dsRed for the 
forward and reverse TALENs respectively) in the same cells and allowed the 
identification of TALEN expressing cells. However, we could not efficiently infect the 
NIH 3T3 cell line using these TALEN retroviral constructs. Although we achieved 
approximately 40% infection efficiency with virus generated from control vector 
backbones, demonstrating the infectibility of these NIH3T3 cells, TALEN encoding 
vectors (which are considerably larger) could not produce infectious virus. This 
indicates that the large molecular weight of TALEN constructs could be the limiting 
factor for virus production in the Phoenix cell line.  
 
Another possibility is that infected and stably TALEN expressing cells could not 
survive due to the genotoxic effects of TALENs. But this is an unlikely possibility as 
we could later generate TALEN expressing (albeit not stably) cell lines. Possibly, off-
target mutations may result in cells stably expressing TALENs to be at a relative 
disadvantage to untransfected cells or to those cells that lost TALEN expression. During 
the course of this study we realized that in fact stably expressing TALENs is not 
desired. To reduce off target effects, TALENs should only transiently be expressed in 
cells. After inducing double stranded breaks (DSBs) at the desired endogenous loci, the 
expression of TALEN constructs is no longer necessary and may be deleterious to the 
mutation containing cells. Therefore, we decided to express TALEN constructs 
ectopically.  
 
Although transient transfection and expression could be achieved using our 
retroviral plasmid constructs, used for virus production, we generated new mammalian 
expression plasmids containing TALEN-IRES-fluorescent reporters. These constructs 
contained a CMV promoter, which is much stronger than the LTR of the retroviral 
vector construct. The transfection efficiency of Neuro-2a cells transfected with both an 
IRES-eGFP and IRES-dsRed TALEN expressing plasmids was around 30%.This is half 
of the normal transfection efficiency in this cell line. Perhaps the size of the fluorescent 
TALEN pair constructs limits the transfection of these cells, as in the case for our 
infection experiments. During the course of this study, we learned that efficient TALEN 
cleavage is influenced greatly by the presence of a C-terminally truncated protein. 
Unfortunately, the TALEN pair targeting the IL7R GR binding site was in a scaffold 
containing long C-terminal segments [6]. In addition, the GR TALEN pair was 
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synthesized using NK RVDs to target G bases. We also recently learned that NK 
containing RVDs have a lower affinity for G bases as compared to NN RVDs [14]. For 
these reasons, we discontinued our experiments with the commercially designed 
TALEN pair targeting the GR binding site and focused our attention to the TALEN 
pairs targeting other sites in the IL7R gene enhancer. We constructed these second 
generation TALENs to contain only NN RVDs to target G’s and in the plasmid 
backbones (pCAGT7 and pC-Goldy) which have the appropriate C-terminal truncation 
necessary for efficient DNA cutting. 
 
 Thus, we assembled TALEN constructs targeting the Notch and NF-κB binding 
sites using the Golden Gate TALEN kit. The pCAGT7 plasmid that contains a CAG 
promoter for mammalian expression was used as a final destination plasmid in TALEN 
assembly. Formation of homodimers (instead of heterodimers) by TALEN monomers 
decreases the cutting efficiency and results in off-target cleavage. Research on FokI 
enzyme dimerization indicated that homodimerization could be prevented by using 
mutants in the dimerization interface. New TALEN backbone plasmids were developed 
during the course of this study which we acquired, that use mutant FokI domains for 
each TALEN monomer[45]. We used these mutant FokI destination plasmids when 
generating TALEN monomers targeting the Notch binding site. More recently, the 
Goldy TALEN scaffold was reported to have improved genome editing efficiency 
compared to other TALEN encoding backbones[35]. Goldy TALENs contain drastically 
truncated N and C terminal domains. This modification is likely necessary for the 
assembly of the TALEN protein on the target site and the appropriate orientation of the 
FokI domains on the spacer region. We therefore transferred both the Notch and NF-κB 
TALENs into the Goldy TALEN backbone. 
 
Indeed, in experiments where we compared the cutting efficiency of TALENs 
targeting the Notch site, with identical DNA binding domains expressed in the context 
of pCAGT7, pCAGT7-mutant FokI and pC-Goldy TALEN backbones, we found that 
Goldy TALENs were the best cutters! (Figure 4.21) These experiments were conducted 
in RLM11 cells. The intensity of the uncut band was found to be the highest for the 
Notch TALEN pair in the Goldy backbone, consistent with recently published results. 
We found that band intensity was the lowest for TALEN pairs in the backbone with 
mutant FokI domains. This result is not consistent with previously published work, as 
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the mutant FokI domain was shown to have increased cutting efficiencies as well as 
higher specificity. Further evaluation of the cut site efficiency by normalizing the 
amount of expressed TALEN proteins may be necessary to explain this discrepancy.  
 
 
  In addition to scaffold optimizations during TALEN assembly, there are some 
critical points that have to be taken into consideration for detecting mutations generated 
by these proteins. First of all, in all TALEN expression experiments, we subjected cells 
to transient hypothermia after transfection, by incubating at 32°C instead of 
37°C.Transient hypothermia was previously shown to increase mutation efficiency both 
in zinc finger nucleases and in TALENs[6, 82]. This effect likely increases the folding 
efficiency of TALEN proteins that have to adopt a super helical structure. It is also 
possible that decreased temperatures decreases the progression of the cell cycle, giving 
more time for the generated DSBs to be repaired by NHEJ. It would therefore be 
interesting to test the mutation profile of cells that express TALENs in the presence and 
absence of hypothermia. We also harvested, transfected cells 72 hours after transfection 
to allow for time necessary for TALEN expression, double stranded break (DSBs) 
generation and NHEJ mediated repair of induced DSBs. It may be necessary to optimize   
the time of incubation to prevent toxicity to cells that may result in an apparent increase 
in the mutation rate.  
 
 Detection of induced mutations was another critical rate limiting point in this 
project. Transfection efficiency, efficiency of TALENs to induce double stranded 
breaks, the capacity of the transfected cell line for DNA repair and the mutation of 
either one or both chromosomes, the unknown ploidy of the cancer cells being used are 
all parameters that influence the number of mutant alleles in genomic DNA isolated 
from pooled cells. All of these listed parameters may result in restriction resistant PCR 
products in the restriction fragment length polymorphism (RFLP) assay. In order to 
detect a mutated allele from a genomic DNA pool of cells, we modified the RFLP assay 
by first digesting the genomic DNA with the enzyme in the spacer region, before 
amplifying the genomic DNA by PCR and re-digestion with the RFLP enzyme. We 
reasoned that the digestion of genomic DNA would decrease the number of wild type 
alleles in the in the pool of genomic DNA to be amplified and that the relative fraction 
of mutant alleles would increase. Theoretically, the initial restriction enzyme digest of 
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genomic DNA should remove all wild type alleles from the PCR template pool, but 
digestion of genomic DNA may not be as efficient as digestion of purified plasmid 
DNA. In figures 4.19, 4.21, and 4.28, we show experiments where we PCR amplified 
the TALEN target region from digested genomic DNA used as a template followed by a 
second restriction digestion of the PCR amplicon. In this modified RFLP assay we 
could detect restriction resistant mutant alleles that show up as an uncut band with the 
same size of the undigested PCR product. Because we had to use this enrichment step, 
we could not quantify the mutagenesis frequency in the pool of cells that contain 
TALEN induced mutations [5]. All the mutations detected in this study for both the 
Notch and NF-κB TALENs involve this enrichment step.  
 
Actually, the modified RFLP assay underestimates the number of mutations 
created at the TALEN target site because only mutant alleles that are restriction enzyme 
resistant are scored. It is likely that there are many mutant alleles generated along those 
that lose the restriction enzyme binding site, that do not lose this site. Because our 
sequencing results are derived from restriction enzyme resistant PCR amplicons cloned 
from the modified RFLP assay, these results are also underestimating the number of 
possible mutants in the pool of TALEN treated cells. Therefore we think that both the 
RFLP and the sequencing results we provide are an underestimation of the mutant 
alleles produced by these TALENs.   
 
 We tested the induction of mutations by TALENs targeting the IL7R Notch site 
in both the Neuro-2a and RLM11 cells using the modified RFLP assay. Neuro-2a cells 
were not appropriate for phenotypic analysis as they are neurons that do not express 
IL7Rα. However, previous work shows that NHEJ is very efficient in this cell line, 
making them a good candidate for detecting TALEN induced mutations. The RLM11 
cell line is IL7Rα positive and the phenotypic effect of induced mutations could be 
analyzed phenotypically. Our sequencing results provide evidence for mutant alleles 
that have deletions, insertions and single nucleotide polymorphisms at the target site. 
The most frequent mutation we detected was a deletion of one nucleotide. Indeed the 
same nucleotide was deleted in both the RLM11 and Neuro-2a cell lines. This may 
indicate that during NHEJ, mutations occur in an additive manner, starting with one 
base pair deletion and evolving to have various additional mutations. In addition, the 
frequency of mutations with 4 bp and 9 bp deletions were the same for both cell lines.  
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Although the number of colonies screened for the Neuro-2a cell line is more 
than that for RLM11 cells, the number of different mutations detected was higher in the 
RLM11 cell line. In fact the number of observed SNPs was also higher in RLM11 cells. 
This result may indicate that IL7Rα expression may be priming the genomic locus to 
become more susceptible to mutation. It is well known that transcriptionally active gene 
loci are devoid of histone proteins. Thus it is possible that the target site is more 
available for TALEN binding and DSB generation in the IL7R expressing RLM11 cell 
line compared to non-expressing Neuro-2a cells. In a recent study, it was demonstrated 
that the use of constructed TALE proteins together with epigenetic inhibitors enhanced 
transcriptional activation rate of epigenetically silenced genes [83]. Moreover, it was 
shown that the TALEN induced mutation rate was negatively correlated with the 
number of CpG targets in the target site[34].Our results that indicate a higher frequency 
of mutations in the target site in cells expressing the IL7R are consistent with these 
results. 
 
 To analyze the mutations generated by the NF-κB TALENs transfected to 
RLM11 cells in the Goldy backbone, we cloned and sequenced the uncut band obtained 
after the modified RFLP assay. We found four different mutations with deletions of 
either 15 or 16 nucleotides and one or two SNPs were detected in the 40 colonies 
screened. As expected, the restriction site in all sequenced clones was destroyed. 
Surprisingly, the NF-κB binding site was not destroyed in any of the mutants. This 
result seems contradictory to our finding that IL7R expression was decreased in these 
clones. It is possible that yet another transcription factor right next to the NF-κB binding 
site is present in this enhancer, and that this transcription factor is necessary for IL7R 
expression. Although the NF-κB binding site was intact, a 15 bp-deletion corresponds to 
one and half turn of the DNA helix and this modification may in fact result in a loss of a 
necessary interaction between NF-κB and close-by nuclear factors binding to the 
enhancer. It is well known that enhancers function by multiple transcription factors 
binding in close proximity on the DNA. The concept of an enhanceosome requires that 
these DNA binding factors fit like pieces of a puzzle and that any alteration in the 
spacing between the binding sites dramatically affects transcription factor interaction 
and enhancer activity.  
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Although we observed a small decrease in the IL-7Rα expression in NF-κB 
binding site TALEN transfected RLM11 cells, expression was unchanged in Notch 
binding site TALEN transfected cells. Although we do not know the frequency, both 
TALENs were capable of generating mutated cells in the pool of transfected cells. The 
use of a heterogeneous cell pool to assess IL-7Rα expression on Notch site TALEN 
transfected cells may not be sensitive enough to detect changes in expression. Assuming 
that the NF-κB site TALEN transfected cell pool has a similar complexity and results in 
a detectable decrease in IL-7Rα expression we could conclude that mutations in the 
Notch binding site (RBP-Jk)alone does not affect IL-7R expression. Current dogma 
indicates that Notch needs to be activated, cleaved from the plasma membrane, 
translocated to the nucleus, associate with the RBP-Jk protein and displaces previously 
bound suppressors to activate transcription. These cellular events may not be happening 
in the chosen cell line mutant. Thus the same mutants that do not affect IL7R expression 
may in fact be important in other cell types. 
 
Although mutations were detected in TALEN target regions and the phenotypic 
effect of mutations was demonstrated on IL-7Rα expression, selecting TALEN 
transfected cells is important to quantify TALEN mutagenesis frequency. It is possible 
to select high TALEN expressing cells by co-transfecting TALEN pairs with a GFP 
plasmid and sorting GFP positive cells by flow cytometry[84]. However, as indicated in 
a recent study, sorted cells sometimes cannot form colonies due to damage from the 
strong laser and hydrostatic pressure they are exposed to in the FACS machine. Sorting 
of TALEN transfected cells can also be achieved by magnetic separation or antibiotic 
selection using reporter systems in which a selectable marker is expressed only when 
mutations are generated at the TALEN target site [85]. In fact in data not included in 
this thesis, we attempted to sort TALEN transfected and IL7R low expressing cells by 
magnetic bead separation. Unfortunately we could not detect any mutations in these 
sorted populations. Ultimately, in order to assign a single phenotype to a single cell with 
a single mutation, it is necessary to generate clonal populations from sorted cell pools. 
We are currently attempting to single cell clone Notch and NF-κB site mutated cells 
from our pools.  
 
 In the final section of this thesis, we generated six TALE repeat arrays that we 
thought could function as competitive inhibitors for an NF-κB binding site. Rather than 
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being fused to a DNA cleaving FokI restriction enzyme domain, these TALE DNA 
binding domains were fused to a DsRed fluorescent protein encoding domain. These 
constructs were expressed in the context of the FokI sequence deficient pCAGT7 
derived mammalian expression plasmid named pCAGdsRed. We generated and 
transfected six TALEdsRed constructs with different repeat numbers into the HEK293 
6.1.1 cell line, constructed previously by Pinar Onal and Belkis Atasever in our lab. 
This reporter cell line has stably integrated four NF-κB binding sites controlling the 
human c-Fos promoter driving the expression of an eGFP gene. This cell line responds 
to TNF-α treatment by upregulating GFP expression as a result of NF-κB nuclear 
translocation. We found that our TALE-dsRed constructs suppressed GFP expression 
upon TNF-α induction. This effect was specific to those cells that were dsRed positive 
indicating that the TALE-dsRed bound to the reporter construct NF-κB sites in place of 
NF-κB. In fact GFP expression of dsRed positive cells was more that 4-fold decreased 
compared to untransfected cells. 
 
 It is known that dsRed proteins can result in tetramerization of fusion proteins. 
Our reporter cell line contains four NF-κB sites integrated into its genome. We have not 
yet assessed whether our TALEdsRed proteins form tetramers and whether this putative 
interaction plays a role in DNA binding. On the other hand, dsRed tetramerization 
before the TALE proteins bind DNA may be decreasing the affinity of these fluorescent 
transcription factors to the DNA and perhaps limiting the NF-κB competitive inhibition 
activity. In such a scenario, it may be more advantageous to express the TALE DNA 
binding domain independently of the fluorescent protein domain. We note that our 
TALEdsRed constructs were assembled in a plasmid optimized for TALEN induced 
genome modification. This plasmid has been optimized for DNA cleavage by a C-
terminal truncation. Earlier reports show that the optimal TALE DNA binding domain 
structure for cleavage and gene regulation activities differs [6].Thus our TALEdsRed 
constructs may require more optimization for a more robust DNA binding competitive 
effect. 
 
An important control for our competitive binding experiment, involves the 
demonstration that a TALE dsRed construct that does not have specificity to NF-κB 
does not inhibit NF-κB activity. We are currently constructing such a construct. We also 
note that, TNF-α treatment was initiated 30 hours after the transfection of the 
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TALEdsRed constructs and that we analyzed these cells after a 9 hour TNF-α treatment. 
GFP expression in untransfected cells was around 60%, although this was expected to 
be 100%, as this is a stable cell line. This indicates that TNF-α treatment should be 
optimized, perhaps by using confocal microscopy to show that a majority of treated 
cells express GFP and TALEdsRed proteins. Confocal microscopy can also be used to 
demonstrate that TALEdsRed and NF-κB proteins are co-localized in the nucleus at the 
same time. Under these controlled settings, an optimal transcription inhibition activity 
of our constructed TALE inhibitor proteins can be assessed. 
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6. CONCLUSION 
 
 In this study, our main aim was to create mutations at the nuclear factor binding 
sites of the endogenous IL-7Rα gene locus using TALEN technology. This line of work 
is important for understanding the roles of these transcription factor proteins for the 
transcription regulation of this immunologically important gene. We used three different 
strategies to design and construct different TALEN proteins targeting three sites in the 
IL7R gene. The literature indicates that these sites are bound by the transcription 
factors, GR, Notch and NF-κB. While we were not successful in generating active 
TALENs using the first two strategies, the final strategy of expressing TALENs in the 
context of the pC-Goldy expression system yielded active TALENs and we were able to 
detect INDELs at the targeted sites. We detected the induction of mutations at the 
targeted sites using a modified RFLP assay and subsequently sequenced PCR products 
from these regions to demonstrate that INDELs were actually being generated 
specifically at the target site. We do not currently know the off target specificity of 
these TALENs and whether mutations were incorporated at different sites of the 
genomes of these targeted cells. We analyzed the effect of these mutations on IL-7Rα 
expression in a heterogeneous mutated cell pool by flow cytometry and found that 
mutations generated by the TALEN targeting the NF-κB binding site indeed reduced 
IL-7Rα expression. On the other hand, mutations induced by the TALEN targeting the 
Notch binding site did not detectably affect IL-7Rα expression. We did not assess the 
mutagenic potential of the TALEN targeting the GR binding site. These experiments 
show that TAL effector nucleases can be used for mutation of endogenous genomic 
transcription enhancers to conduct structure-function studies on these sequences in the 
endogenous genomic context. Currently most transcription enhancer structure uses the 
luciferase reporter plasmid expression system which is admittedly an overexpression 
system and may not reflect the true activity of endogenous enhancers. In this study we 
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demonstrate that individual transcription factor binding sites in endogenous enhancers 
can be mutated to affect transcriptional enhancer activity to study function. 
 In this study we also assessed transcription factor activity using a second 
approach. In addition to using TALENs for site directed mutagenesis of enhancers, we 
constructed plasmids encoding TALEdsRed fusion proteins to create competitive 
binders of an NF-κB transcription factor binding site. To achieve this aim we used a 
previously generated stable cell line (named HEK293 6.1.1), in which TNF-α treatment 
results in GFP expression due to NF-κB nuclear translocation. This cell line contains a 
stably integrated construct containing four NF-κB binding sites controlling a minimal 
human c-Fos gene promoter driving the expression of an eGFP gene. We demonstrated 
by flow cytometry that TALEdsRed expression resulted in a reduction of GFP 
expression in TNF-α treated cells. This part of the study demonstrates that TAL effector 
proteins can be used as competitive inhibitors of nuclear factors to inhibit gene 
transcription. 
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APPENDIX 
 
APPENDIX A: Chemicals Used in the Study 
 
Chemicals Supplier Company 
Acetic Acid Sigma, Germany 
Agarose Sigma, Germany 
Ampicillin sodium salt Cellgro, USA 
Boric acid Molekula, UK 
Calcium chloride Sigma, Germany 
Distilled water Milipore, France 
DMEM Gibco, USA 
DMSO Sigma, Germany 
EDTA Sigma, Germany 
Ethanol Sigma, Germany 
Ethidium bromide Sigma, Germany 
Fetal Bovine Serum (FBS) Lonza, Switzerland 
Glycerol Sigma, Germany 
HBSS Gibco, USA 
Hydrochloric Acid Sigma, Germany 
Isopropanol Sigma, Germany 
Kanamycin Sulfate Gibco, USA 
LB Agar BD, USA 
LB Broth Sigma, Germany 
L-glutamine Hyclone, USA 
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Liquid nitrogen Karbogaz, Turkey 
2-mercaptoethanol Sigma, Germany 
Penicillin-Streptomycin Sigma, Germany 
PIPES Sigma, Germany 
PBS Sigma, Germany 
RNase A Roche, Germany 
RPMI 1640 Gibco, USA 
SDS Sigma, Germany 
Sodium Azide Amresco,USA 
Spectinomycin Sigma, Germany 
Tetracyclin Sigma, Germany 
Tris base Sigma, Germany 
Trypan Blue Fluca, Germany 
Trypsin-EDTA Gibco, USA 
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APPENDIX B: Equipment Used In the Study 
 
Equipment Company 
Autoclave Priorclave, UK 
Balance Sartorius, BP221S, Germany 
Schimadzu, Libror EB-3200 HU, Japan 
Centrifuge Hitachi, Sorvall RC5C Plus, USA 
Eppendorf, 5415D, Germany 
Eppendorf, 5418R, Germany 
Beckman Coulter, Allegra®X-15R, USA 
CO2 Incubator Binder,Germany 
Deepfreeze -80°C, Forma,Thermo ElectronCorp.,USA 
-20°C,Bosch,Turkey 
Distilled Water Millipore, Elix-S, France 
Electrophoresis Apparatus Biorad Inc., USA 
Electroporator Invitrogen, Neon Transfection Systems, USA 
Flow Cytometer BD FACS Canto,USA 
Gel Documentation Biorad, UV-Transilluminator 2000, USA 
Heater ThermomixerComfort,Eppendorf,Germany 
Hematocytometer Hausser Scientific,Blue Bell Pa.,USA 
Ice Machine Scotsman Inc.,  AF80, USA  
Incubator Memmert, Modell 300, Germany 
Laminar Flow Kendro Lab. Prod., Heraeus, HeraSafe HS12, 
Germany 
Liquid Nitrogen Tank Taylor-Wharton,3000RS,USA 
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Magnetic Stirrer StuartTM,SB162, UK 
Microliter Pipettes Gilson, Pipetman, France 
Microscope Olympus IX70, Japan 
Olympus CK40, Japan 
Microwave Oven Bosch,Turkey 
pH meter Mettler Toledo, S220 SevenCompactTM 
pH/Ion, USA 
Refrigerator Bosch,Turkey 
Shaker Incubator New Brunswick Sci., Innova 4330, USA 
Spectrophotometer Amersham Biosciences, UK 
Thermocycler 
 
Eppendorf, Mastercycler Gradient, 
Germany 
Vortex Velp Scientifica,Italy 
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APPENDIX C: DNA Molecular Weight Marker 
 
 
 
Gene RulerTM DNA Ladder Mix 
Fermentas, Germany 
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APPENDIX D: FACS Analysis of GFP and dsRed Expression Levels in NIH3T3 
Cell Line Infected with ECR3 GR Binding Site TALEN plasmids 
 
Figure D.1 FACS analysis of GFP and dsRed expression in ECR3 GR binding site 
TALEN infected NIH3T3 cell line. The first column shows side scatter vs. forward 
scatter dot plots, the second column shows histograms of GFP expression and the third 
column shows histograms of dsRed expression. . a) Uninfected NIH3T3 b) pMIGII 
TcRαβ-IRESdsRed and pMIGII-IRESdsRed infected NIH3T3 cells c) Left GR binding 
site TALEN-IRESGFP and right GR binding site TALEN-IRESdsRed infected NIH3T3 
cells. Forward scatter, shows the size of the cells and side scatter shows the granularity 
of cells. The analysis was restricted to the live cells falling into the gate shown in side 
scatter vs. forward scatter dot plots. The percentage of cells falling into each gate is 
indicated under the label for each gate.   
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APPENDIX E: FACS Analysis of GFP and dsRed Expression Levels in Neuro-2a 
Cell Line Transfected with CMV ECR3 GR Binding Site TALEN Plasmids 
 
Figure E.1 FACS analysis of GFP and dsRed expression in CMV ECR3 GR binding site 
TALEN transfected Neuro-2a cell line. The first column shows side scatter vs. forward 
scatter dot plots, the second column shows histograms of GFP expression and the third 
column shows histograms of dsRed expression. . a) Untransfected Neuro-2a b) CMV 
left GR binding site TALEN-IRESGFP and CMV right GR binding site TALEN-
IRESdsRed co-transfected Neuro-2a cells. Forward scatter, shows the size of the cells 
and side scatter shows the granularity of cells. The analysis was restricted to the live 
cells falling into the gate shown in side scatter vs. forward scatter dot plots. The 
percentage of cells falling into each gate is indicated under the label for each gate. 
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APPENDIX F: FACS Analysis of IL7Rα Expression Levels on RLM11 Cell Line 
Transfected with Constructed TALEN Plasmids 
 
Figure F.1 FACS analysis of IL7Rα expression on the RLM11 cell line transfected with 
TALEN expression plasmids targeting NF-κB binding site and Notch binding site of IL-
7R enhancer region. The first column shows side scatter vs. forward scatter dot plots, 
the second column shows histograms of IL-7Rα expression. a) untransfected RLM11 b) 
pC-Goldy NF-κB binding site TALEN pair transfected RLM11 cells c) pC-Goldy Notch 
binding site TALEN pair transfected RLM11 cells. Forward scatter, shows the size of 
the cells and side scatter shows the granularity of cells. The analysis was restricted to 
the live cells falling into the gate shown in side scatter vs. forward scatter dot plots. The 
bold numbers inside the graph indicates the mean Alexa 647 fluorescence intensity of 
the cells, indicating IL7R expression. IL7Rα was detected with biotinylated CD127 
antibodies followed by Alexa647 labeled streptavidin. The percentage of cells falling 
into each gate is indicated under the label for each gate.   
 
122 
 
APPENDIX G: Representative Sequence Analysis of Mutations Induced at Notch 
Binding Site TALEN Target Sites of Neuro-2a Cells 
 
Figure G.1 Sequencing analysis of the Notch binding site TALEN transfected Neuro-2a 
cells. Green arrow represents the binding site of left Notch TALEN. Red arrow 
represents the binding site of right Notch TALEN. The numbers on the left indicates the 
number of nucleotides inserted or deleted. WT corresponds to the sequence of Notch 
binding site TALEN target site of the untransfected Neuro-2a cells. 
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APPENDIX H: FACS Analysis of GFP Expression Levels in HEK293 6.1.1 
Reporter Cell Line Transfected with TALEdsRed Expression Plasmids 
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Figure H.1 FACS analysis of GFP expression in transfected HEK293 6.1.1 reporter cell 
line. The first column shows side scatter vs. forward scatter dot plots, the second 
column shows histograms of GFP expression and the third column shows histograms of 
dsRed expression. a) untransfected TNF untreated b) untransfected TNF treated c) 
TALEdsRed12 transfected TNF untreated d) TALEdsRed12 transfected TNF treated e) 
TALEdsRed13 transfected TNF untreated f) TALEdsRed13 transfected TNF treated 
g)TALEdsRed14 transfected TNF untreated h) TALEdsRed14 transfected TNF treated 
i)TALEdsRed15 transfected TNF untreated j) TALEdsRed15 transfected TNF treated 
k)TALEdsRed16 transfected TNF untreated l) TALEdsRed16 transfected TNF treated 
m)TALEdsRed17 transfected TNF untreated n) TALEdsRed17 transfected TNF treated 
HEK293 6.1.1 cells. Forward scatter, shows the size of the cells and side scatter shows 
the granularity of cells. The analysis was restricted to the live cells falling into the gate 
shown in side scatter vs. forward scatter dot plots. The bold numbers inside the graph 
indicates the mean GFP fluorescence intensity of the cells in the gates. The percentage 
of cells falling into each gate is indicated under the label for each gate.   
 
 
 
 
 
